MXPA00007893A - Targeting of genetic vaccine vectors. - Google Patents
Targeting of genetic vaccine vectors.Info
- Publication number
- MXPA00007893A MXPA00007893A MXPA00007893A MXPA00007893A MXPA00007893A MX PA00007893 A MXPA00007893 A MX PA00007893A MX PA00007893 A MXPA00007893 A MX PA00007893A MX PA00007893 A MXPA00007893 A MX PA00007893A MX PA00007893 A MXPA00007893 A MX PA00007893A
- Authority
- MX
- Mexico
- Prior art keywords
- recombinant
- cells
- cell
- library
- nucleic acid
- Prior art date
Links
- 230000002068 genetic effect Effects 0.000 title claims abstract description 156
- 229960005486 vaccine Drugs 0.000 title claims abstract description 146
- 239000013598 vector Substances 0.000 title claims description 230
- 230000008685 targeting Effects 0.000 title description 6
- 238000000034 method Methods 0.000 claims abstract description 213
- 230000001965 increasing effect Effects 0.000 claims abstract description 20
- 210000004027 cell Anatomy 0.000 claims description 415
- 108090000623 proteins and genes Proteins 0.000 claims description 166
- 150000007523 nucleic acids Chemical class 0.000 claims description 153
- 102000039446 nucleic acids Human genes 0.000 claims description 147
- 108020004707 nucleic acids Proteins 0.000 claims description 147
- 230000027455 binding Effects 0.000 claims description 130
- 238000009739 binding Methods 0.000 claims description 130
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 115
- 108091007433 antigens Proteins 0.000 claims description 111
- 102000036639 antigens Human genes 0.000 claims description 110
- 239000000427 antigen Substances 0.000 claims description 107
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 106
- 229920001184 polypeptide Polymers 0.000 claims description 102
- 108091033319 polynucleotide Proteins 0.000 claims description 91
- 102000040430 polynucleotide Human genes 0.000 claims description 91
- 239000002157 polynucleotide Substances 0.000 claims description 91
- 108020004414 DNA Proteins 0.000 claims description 79
- 102000004169 proteins and genes Human genes 0.000 claims description 79
- 238000000926 separation method Methods 0.000 claims description 66
- 238000005215 recombination Methods 0.000 claims description 52
- 230000006798 recombination Effects 0.000 claims description 52
- 210000001519 tissue Anatomy 0.000 claims description 50
- 230000014509 gene expression Effects 0.000 claims description 44
- 239000000147 enterotoxin Substances 0.000 claims description 39
- 231100000655 enterotoxin Toxicity 0.000 claims description 39
- 241001465754 Metazoa Species 0.000 claims description 38
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 36
- 241001515965 unidentified phage Species 0.000 claims description 36
- 102000005962 receptors Human genes 0.000 claims description 34
- 108020003175 receptors Proteins 0.000 claims description 34
- 238000012360 testing method Methods 0.000 claims description 32
- 230000009870 specific binding Effects 0.000 claims description 28
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 claims description 24
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 claims description 23
- 210000004443 dendritic cell Anatomy 0.000 claims description 23
- 101710146739 Enterotoxin Proteins 0.000 claims description 22
- 241000124008 Mammalia Species 0.000 claims description 22
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 22
- 108020001507 fusion proteins Proteins 0.000 claims description 22
- 102000037865 fusion proteins Human genes 0.000 claims description 22
- 239000002773 nucleotide Substances 0.000 claims description 22
- 125000003729 nucleotide group Chemical group 0.000 claims description 22
- 241000588724 Escherichia coli Species 0.000 claims description 20
- 238000010521 absorption reaction Methods 0.000 claims description 20
- 239000003446 ligand Substances 0.000 claims description 20
- 230000004927 fusion Effects 0.000 claims description 19
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 17
- 230000001580 bacterial effect Effects 0.000 claims description 16
- 101710198693 Invasin Proteins 0.000 claims description 15
- 230000004044 response Effects 0.000 claims description 15
- 108091007494 Nucleic acid- binding domains Proteins 0.000 claims description 14
- 210000001616 monocyte Anatomy 0.000 claims description 14
- 230000001717 pathogenic effect Effects 0.000 claims description 14
- 238000001890 transfection Methods 0.000 claims description 14
- 210000003491 skin Anatomy 0.000 claims description 12
- 230000001939 inductive effect Effects 0.000 claims description 11
- 244000052769 pathogen Species 0.000 claims description 11
- 108010033040 Histones Proteins 0.000 claims description 9
- 238000001990 intravenous administration Methods 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 238000005406 washing Methods 0.000 claims description 9
- 230000004568 DNA-binding Effects 0.000 claims description 8
- 241000607626 Vibrio cholerae Species 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 210000001821 langerhans cell Anatomy 0.000 claims description 8
- 210000000663 muscle cell Anatomy 0.000 claims description 8
- 108010001857 Cell Surface Receptors Proteins 0.000 claims description 7
- 102000000844 Cell Surface Receptors Human genes 0.000 claims description 7
- 230000035755 proliferation Effects 0.000 claims description 7
- 238000012258 culturing Methods 0.000 claims description 6
- 210000005260 human cell Anatomy 0.000 claims description 6
- 210000002540 macrophage Anatomy 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 230000000699 topical effect Effects 0.000 claims description 6
- 230000030741 antigen processing and presentation Effects 0.000 claims description 5
- 210000002510 keratinocyte Anatomy 0.000 claims description 5
- 230000001926 lymphatic effect Effects 0.000 claims description 5
- 210000004698 lymphocyte Anatomy 0.000 claims description 5
- 241000282693 Cercopithecidae Species 0.000 claims description 4
- 230000017531 blood circulation Effects 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 4
- 238000000576 coating method Methods 0.000 claims description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 4
- 210000000952 spleen Anatomy 0.000 claims description 4
- 101150013553 CD40 gene Proteins 0.000 claims description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 3
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 3
- 210000001165 lymph node Anatomy 0.000 claims description 3
- 230000003472 neutralizing effect Effects 0.000 claims description 3
- 231100000252 nontoxic Toxicity 0.000 claims description 3
- 230000003000 nontoxic effect Effects 0.000 claims description 3
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 2
- 108010049003 Fibrinogen Proteins 0.000 claims description 2
- 102000008946 Fibrinogen Human genes 0.000 claims description 2
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 2
- 102000007327 Protamines Human genes 0.000 claims description 2
- 108010007568 Protamines Proteins 0.000 claims description 2
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 2
- 230000001461 cytolytic effect Effects 0.000 claims description 2
- 229940104302 cytosine Drugs 0.000 claims description 2
- 229940012952 fibrinogen Drugs 0.000 claims description 2
- 229940027941 immunoglobulin g Drugs 0.000 claims description 2
- 230000002103 transcriptional effect Effects 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- 239000011701 zinc Substances 0.000 claims description 2
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 claims 1
- 230000004570 RNA-binding Effects 0.000 claims 1
- 230000037406 food intake Effects 0.000 claims 1
- 210000004400 mucous membrane Anatomy 0.000 claims 1
- 229940048914 protamine Drugs 0.000 claims 1
- 229940124856 vaccine component Drugs 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 12
- 235000018102 proteins Nutrition 0.000 description 66
- 239000003981 vehicle Substances 0.000 description 39
- 239000000203 mixture Substances 0.000 description 28
- 241000282414 Homo sapiens Species 0.000 description 23
- 238000001727 in vivo Methods 0.000 description 21
- 239000013612 plasmid Substances 0.000 description 18
- 238000012546 transfer Methods 0.000 description 18
- 230000028993 immune response Effects 0.000 description 17
- 239000003550 marker Substances 0.000 description 17
- 239000002253 acid Substances 0.000 description 16
- 230000006872 improvement Effects 0.000 description 15
- 239000003053 toxin Substances 0.000 description 15
- 231100000765 toxin Toxicity 0.000 description 15
- 108700012359 toxins Proteins 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 238000009396 hybridization Methods 0.000 description 14
- 102000004127 Cytokines Human genes 0.000 description 12
- 108090000695 Cytokines Proteins 0.000 description 12
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 description 12
- 150000007513 acids Chemical class 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 12
- 229940024606 amino acid Drugs 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 11
- 238000000684 flow cytometry Methods 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 108020004705 Codon Proteins 0.000 description 10
- 241000700605 Viruses Species 0.000 description 10
- 230000008901 benefit Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- 102000009016 Cholera Toxin Human genes 0.000 description 9
- 108010049048 Cholera Toxin Proteins 0.000 description 9
- 125000003275 alpha amino acid group Chemical group 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 238000002703 mutagenesis Methods 0.000 description 9
- 231100000350 mutagenesis Toxicity 0.000 description 9
- 238000002823 phage display Methods 0.000 description 9
- 108010041986 DNA Vaccines Proteins 0.000 description 8
- 229940021995 DNA vaccine Drugs 0.000 description 8
- 230000000890 antigenic effect Effects 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 8
- 102000044158 nucleic acid binding protein Human genes 0.000 description 8
- 108700020942 nucleic acid binding protein Proteins 0.000 description 8
- 230000028327 secretion Effects 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 229920001817 Agar Polymers 0.000 description 7
- 101710096438 DNA-binding protein Proteins 0.000 description 7
- 208000014197 Fetal anticonvulsant syndrome Diseases 0.000 description 7
- 206010024264 Lethargy Diseases 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 239000008272 agar Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 239000005090 green fluorescent protein Substances 0.000 description 7
- 238000005457 optimization Methods 0.000 description 7
- 108091026890 Coding region Proteins 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 6
- 108090000978 Interleukin-4 Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 108010055409 ganglioside receptor Proteins 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 230000010354 integration Effects 0.000 description 6
- 239000002502 liposome Substances 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 235000002639 sodium chloride Nutrition 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 102000019034 Chemokines Human genes 0.000 description 5
- 108010012236 Chemokines Proteins 0.000 description 5
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000013602 bacteriophage vector Substances 0.000 description 5
- 230000001186 cumulative effect Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000004520 electroporation Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000001415 gene therapy Methods 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000007918 intramuscular administration Methods 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- 101710132601 Capsid protein Proteins 0.000 description 4
- 101710094648 Coat protein Proteins 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 4
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 102000043131 MHC class II family Human genes 0.000 description 4
- 108091054438 MHC class II family Proteins 0.000 description 4
- 101710125418 Major capsid protein Proteins 0.000 description 4
- 102000047918 Myelin Basic Human genes 0.000 description 4
- 101710107068 Myelin basic protein Proteins 0.000 description 4
- 101710141454 Nucleoprotein Proteins 0.000 description 4
- 101710160107 Outer membrane protein A Proteins 0.000 description 4
- 101710083689 Probable capsid protein Proteins 0.000 description 4
- 241000607142 Salmonella Species 0.000 description 4
- 108010022394 Threonine synthase Proteins 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 102000004419 dihydrofolate reductase Human genes 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 238000011239 genetic vaccination Methods 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- -1 polypeptide) Chemical class 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000012797 qualification Methods 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 231100000617 superantigen Toxicity 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- 238000011179 visual inspection Methods 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241001524679 Escherichia virus M13 Species 0.000 description 3
- 241000724791 Filamentous phage Species 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 108010002616 Interleukin-5 Proteins 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 102000004882 Lipase Human genes 0.000 description 3
- 108090001060 Lipase Proteins 0.000 description 3
- 239000004367 Lipase Substances 0.000 description 3
- 102000043129 MHC class I family Human genes 0.000 description 3
- 108091054437 MHC class I family Proteins 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 108091005461 Nucleic proteins Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000002759 chromosomal effect Effects 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 150000002270 gangliosides Chemical class 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 230000002519 immonomodulatory effect Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 230000003308 immunostimulating effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 235000019421 lipase Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 206010069754 Acquired gene mutation Diseases 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 241000589876 Campylobacter Species 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000701959 Escherichia virus Lambda Species 0.000 description 2
- 108091029865 Exogenous DNA Proteins 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- 108091061960 Naked DNA Proteins 0.000 description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 238000011579 SCID mouse model Methods 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 108010079723 Shiga Toxin Proteins 0.000 description 2
- 102100038803 Somatotropin Human genes 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 2
- 230000009824 affinity maturation Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 201000002491 encephalomyelitis Diseases 0.000 description 2
- 231100000249 enterotoxic Toxicity 0.000 description 2
- 230000002242 enterotoxic effect Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 210000000285 follicular dendritic cell Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 238000005462 in vivo assay Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000002934 lysing effect Effects 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000007899 nucleic acid hybridization Methods 0.000 description 2
- 239000002853 nucleic acid probe Substances 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 210000003935 rough endoplasmic reticulum Anatomy 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 229910001415 sodium ion Inorganic materials 0.000 description 2
- 230000037439 somatic mutation Effects 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000002511 suppository base Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 229940118696 vibrio cholerae Drugs 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- AWNBSWDIOCXWJW-WTOYTKOKSA-N (2r)-n-[(2s)-1-[[(2s)-1-(2-aminoethylamino)-1-oxopropan-2-yl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]-n'-hydroxy-2-(2-methylpropyl)butanediamide Chemical compound C1=CC=CC2=CC(C[C@H](NC(=O)[C@@H](CC(=O)NO)CC(C)C)C(=O)N[C@@H](C)C(=O)NCCN)=CC=C21 AWNBSWDIOCXWJW-WTOYTKOKSA-N 0.000 description 1
- VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- ZXXTYLFVENEGIP-UHFFFAOYSA-N 2-amino-3,7-dihydropurin-6-one;3,7-dihydropurine-2,6-dione Chemical compound O=C1NC(N)=NC2=C1NC=N2.O=C1NC(=O)NC2=C1NC=N2 ZXXTYLFVENEGIP-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 239000013607 AAV vector Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108091023043 Alu Element Proteins 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 206010003267 Arthritis reactive Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- CXRFDZFCGOPDTD-UHFFFAOYSA-M Cetrimide Chemical compound [Br-].CCCCCCCCCCCCCC[N+](C)(C)C CXRFDZFCGOPDTD-UHFFFAOYSA-M 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 108010051219 Cre recombinase Proteins 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- LVNMAAGSAUGNIC-BQBZGAKWSA-N Cys-His Chemical compound SC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CNC=N1 LVNMAAGSAUGNIC-BQBZGAKWSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 238000011238 DNA vaccination Methods 0.000 description 1
- 101100239628 Danio rerio myca gene Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000605721 Dichelobacter nodosus Species 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 108010035533 Drosophila Proteins Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
- 241000701867 Enterobacteria phage T7 Species 0.000 description 1
- 241000702374 Enterobacteria phage fd Species 0.000 description 1
- 102000000820 Enterotoxin Receptors Human genes 0.000 description 1
- 108010001687 Enterotoxin Receptors Proteins 0.000 description 1
- 101800001467 Envelope glycoprotein E2 Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102100039869 Histone H2B type F-S Human genes 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 101000930801 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 2 chain Proteins 0.000 description 1
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 101001109800 Homo sapiens Pro-neuregulin-1, membrane-bound isoform Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- 201000008225 Klebsiella pneumonia Diseases 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101150039798 MYC gene Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000011202 Member 2 Subfamily B ATP Binding Cassette Transporter Human genes 0.000 description 1
- 108010023335 Member 2 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 241000588622 Moraxella bovis Species 0.000 description 1
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 241000701980 Phage 434 Species 0.000 description 1
- 206010035717 Pneumonia klebsiella Diseases 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 108010056079 Subtilisins Proteins 0.000 description 1
- 102000005158 Subtilisins Human genes 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 101800001271 Surface protein Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 108010068068 Transcription Factor TFIIIA Proteins 0.000 description 1
- 102100028509 Transcription factor IIIA Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 244000274883 Urtica dioica Species 0.000 description 1
- 235000009108 Urtica dioica Nutrition 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 108070000030 Viral receptors Proteins 0.000 description 1
- 101100459258 Xenopus laevis myc-a gene Proteins 0.000 description 1
- 101100398653 Yersinia pestis lamB1 gene Proteins 0.000 description 1
- 229920000392 Zymosan Polymers 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000008952 bacterial invasion Effects 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 108010079292 betaglycan Proteins 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- UOLRURQSWGZUFP-UHFFFAOYSA-L calcium sodium 2-hydroxypropanoate chloride Chemical compound [Na+].[Cl-].[Ca++].CC(O)C([O-])=O UOLRURQSWGZUFP-UHFFFAOYSA-L 0.000 description 1
- 238000012219 cassette mutagenesis Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 238000009614 chemical analysis method Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- VGONTNSXDCQUGY-UHFFFAOYSA-N desoxyinosine Natural products C1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 VGONTNSXDCQUGY-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000000688 enterotoxigenic effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229940023064 escherichia coli Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 210000001280 germinal center Anatomy 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 102000055691 human APC Human genes 0.000 description 1
- 102000055650 human NRG1 Human genes 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 101150012518 lamB gene Proteins 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 235000020130 leben Nutrition 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 108010020132 microbial serine proteinases Proteins 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000002023 papillomaviral effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 229940070353 protamines Drugs 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 101150079601 recA gene Proteins 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 230000032537 response to toxin Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 238000001612 separation test Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940033134 talc Drugs 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000024033 toxin binding Effects 0.000 description 1
- 108091008023 transcriptional regulators Proteins 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
- C12N15/1027—Mutagenizing nucleic acids by DNA shuffling, e.g. RSR, STEP, RPR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Pulmonology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
This invention provides methods of obtaining reagents for increasing the specificity of genetic vaccines for a desired target cell or tissue type. The invention also provides delivery vehicles for use to improve genetic vaccine specificity for a target cell or tissue type.
Description
DIRECTION OF GENE VACCINE VECTORS
BACKGROUND OF THE INVENTION Field of the Invention This invention belongs to the field of genetic vaccines. Specifically, the invention provides methods for improving the effectiveness of genetic vaccines by providing materials that facilitate the targeting of a genetic vaccine to a particular tissue or cell type of interest.
Background Genetic immunization represents a novel mechanism for inducing protective humoral and cellular immunity. Vectors for genetic vaccines generally consist of DNA that includes a promoter / amplifier sequence operably linked to a gene of interest (which often codes for an antigen) and a polyadenylation / transcriptional terminator sequence. After intramuscular or intradermal injection, the gene of interest is expressed followed by recognition of the resulting protein by the cells of the immune system. Genetic immunizations provide a means to produce protective immunity even in situations where the pathogens are poorly characterized or can not be isolated or cultured in the laboratory environment. The antigen is expressed in the cytoplasm of the host cell (eg, in muscle cells) or, by inclusion of a signal secretion sequence, is expressed on the surface of the host cell or is secreted from the host cell. The antigen is processed by the endogenous processes of the host cell transfected by the gene vaccine vector. When expressed cytoplasmically, it is thought that the antigen will be directed to the proteasome for proteolysis. The peptides thus derived are classified by the endogenous TAP-1 and TAP-2 and transported to the light of the rough endoplasmic reticulum (RER), where they associate with the MHC molecules of Class I to eventually move towards the cell surface as a complex. Molecular Class I, β2-microglobulin and peptide. When the antigen is released intact from the transfected cells, it is thought that it is absorbed by the endocytic pathways in APC and processed internally in them by endogenous pathways for eventual presentation on its cell surface as peptide fragments in complex with MHC molecules of the Class I or II. The effectiveness of genetic vaccination is often limited by the inefficient absorption of the genetic vaccine vectors into the cells. Generally, less than 1% of the muscle or skin cells at the injection sites express the gene of interest. Even a small improvement in the efficiency of gene vaccine vectors to enter cells can result in a dramatic increase in the level of immune response induced by genetic vaccination. A vector typically has to cross many barriers which can result as long as only a very small fraction of the DNA is expressed. Limitations to immunogenicity include: loss of vector due to nucleases present in blood and tissues; inefficient entry of DNA into a cell; inefficient entry of DNA into the cell nucleus and preference of DNA by other compartments; lack of DNA stability in the nucleus (factor that limits nuclear stability may differ from those affecting other cellular and extrecelular compartments), and, by vectors that integrate into the chromosome, the efficiency of the integration and the integration site. In addition, for many applications of genetic vaccines, it is preferable that the genetic vaccine enters a target tissue or particular target cell. Thus, there is a need for genetic vaccines that can be targeted to specific cell types and tissues of interest, and that exhibit a greater ability to enter target cells. The present invention fills those and other needs.
BRIEF DESCRIPTION OF THE INVENTION The present invention provides methods for obtaining a specific binding molecule for a cell that is useful for increasing the absorption or specificity of a genetic vaccine by a target cell. The methods involve: creating a library of recombinant polynucleotides that by recombining a nucleic acid encoding a polypeptide comprising a nucleic acid binding domain and a nucleic acid encoding a polypeptide comprising a specific binding domain of a cells; and separating the library to identify a recombinant polynucleotide that codes for a binding molecule that can bind to a nucleic acid and a specific receptor of a cell. Target cells of particular interest include antigen-presenting and antigen-processing cells, such as muscle cells, monocytes, dendritic cells, B cells, Langerhans cells, keratinocytes and M cells. In some embodiments, the methods of the invention for obtaining a Specific binding portion of a cell useful for increasing the uptake or specificity of a genetic vaccine by a target cell involves: (1) recombining at least a first and second forms of a nucleic acid comprising a polynucleotide that codes for a binding domain of nucleic acid and at least the first and second forms of a nucleic acid comprising a ligand specific for a cell that specifically binds to a protein on the surface of a cell of interest, where the first and second forms differ from each other in two. or more nucleotides, to produce a library of the nucleic acids that it encodes n for the recombinant binding portion; (2) transfect a library of vectors to a population of host cells, each of which comprises: a) a specific binding site for the nucleic acid binding domain and 2) a member of the nucleic acid library that encode for the recombinant binding portion, wherein the recombinant binding portion is expressed and binds to the binding site to form a vector-binding portion complex; (3) lysing the host cells under conditions that do not disturb the binding of the vector-binding portion complex; (4) contacting the vector-binding portion complex with a target cell of interest; and (5) identifying the target cells that contain a vector and isolating the nucleic acids from the specific binding portion of a recombinant cell optimized from those target cells. If further optimization is desired, the methods may further involve: (6) recombining at least one nucleic acid encoding the optimized recombinant binding portion with a further form of the polynucleotide encoding a nucleic acid binding domain and / or an additional form of the polynucleotide encoding a cell-specific ligand, which are the same or different from the first and second forms, to produce an additional library of nucleic acids encoding the recombinant binding portion; (7) transfecting to a population of host cells a library of vectors comprising: a binding site specific for the binding domain of the nucleic acid and 2) the nucleic acids encoding the recombinant binding portion, where the binding portion Recombinant is expressed and binds to the binding site to form a vector-binding portion complex; (8) lysing the host cells under conditions that do not disturb binding of the vector-binding portion complex;
(9) contacting the vector-binding portion complex with a target cell of interest and identifying the target cells containing the vector; (10) isolating the nucleic acids from the optimized recombinant binding portion of the target cells containing the vector; and (11) repeating (6) through (10), as necessary, to obtain a specific binding portion of an additional optimized cell useful for increasing the absorption or specificity of a genetic vaccine vector for a target cell. The invention also provides specific recombinant binding portions of a cells produced by expression in a host cell and a nucleic acid encoding the optimized recombinant binding portion obtained by the methods of the invention. In another embodiment, the invention provides genetic vaccines that include: a) an optimized recombinant binding portion comprising a nucleic acid binding domain and a specific ligand of a cell, and b) a polynucleotide sequence comprising a binding site, wherein the binding domain of the nucleic acid is capable of binding specifically to the binding site. A further embodiment of the invention provides methods for obtaining a specific binding portion of an optimized cell useful for increasing the absorption, efficacy, or specificity of a genetic vaccine for a target cell by: (1) recombining at least one first and second forms of a nucleic acid comprising a polynucleotide, which codes for a non-toxic receptor binding portion of an enterotoxin or other toxin, where the first and second forms differ from each other in two or more nucleotides, to produce a nucleic acid library recombinants 12) by transfecting vectors containing the nucleic acid library in a population of host cells, wherein the nucleic acids are expressed to form the polypeptides of the specific binding portion of a recombinant cell; (3) contacting the polypeptides of the specific binding portion of a cell, recombinants, with a receptor on the cell surface of a target cell; and (4) determining which polypeptides of the specific binding portion of a cell, recombinants, exhibit a greater ability to bind to the target cell. Methods for increasing the uptake of a genetic vaccine vector by a target cell by contacting the vector of the genetic vaccine with a specific binding portion of an optimized recombinant cell produced by those methods are also provided by the invention.
The present invention also provides methods for evolving a vehicle for delivery of a vaccine, gene vaccine vector, or a component of the vector to obtain a vehicle or an optimized release component that has, or confers a vector, enhanced ability to enter to a mammalian tissue selected after administration to a mammal. These methods involve: (1) recombinant members of a set of polynucleotides to produce a library of recombinant polynucleotides; (2) administering to a test animal a library of reproducible genetic packets, each comprising a library member of the recombinant polynucleotides operably linked to a polynucleotide encoding a display polypeptide, wherein the recombinant polynucleotide and the presentation polypeptides are expressed as a fusion protein which is presented on the surface of the reproducible genetic package; and (3) recover reproducible genetic packets that are present in the selected tissue of the test animal at an appropriate time after administration, where the retrievable reproducible genetic packets have a greater ability to enter the selected mammalian tissue after administration to the mammal . If further optimization of the delivery vehicle is desired, the method of the invention further involves: (4) recombining a nucleic acid comprising at least one recombinant polynucleotide obtained from a reproducible genetic package recovered from the selected tissue with an additional set of polynucleotides for produce an additional library of recombinant polynucleotides; (5) administering to a test animal a library of reproducible genetic packets, each comprising a member of an additional library of recombinant polynucleotides operably linked to a polynucleotide encoding a display polypeptide, wherein the recombinant polynucleotide and the presentation polypeptides are expressed with a fusion protein which is presented on the surface of the reproducible genetic package; (6) recover reproducible genetic packages that are present in the selected tissue of the test animal at an appropriate time after administration; and (7) repeating (4) through (6), as necessary, to obtain an optimized recombinant delivery vehicle that exhibits a greater ability to enter a selected mammalian tissue following administration to a mammal. Methods of administration that are of particular interest include, for example, oral, topical and inhalation. Where the administration is intravenous, the mammalian tissues of interest include, for example, the lymph nodes and the spleen. In another embodiment, the invention provides methods for evolving a vaccine delivery vehicle, a genetic vaccine vector, or a vector component to obtain a vehicle or optimized release component to obtain an optimized vector delivery component or carrier that has, or confers to a vector containing the component, greater specificity for cells representing antigens by:
(1) recombining members of a group of polynucleotides to produce a library of recombinant polynucleotides; (2) producing a library of reproducible genetic packets, each comprising a member of the library of recombinant polynucleotides operably linked to a polynucleotide encoding a display polypeptide, wherein the recombinant polynucleotide and the display polypeptide are expressed as a fusion protein which is presented on the surface of the reproducible genetic package; (3) contacting the library of recombinant reproducible genetic packets with a non-APC to remove reproducible genetic packets that have non-APC-specific fusion polypeptides; and (4) contacting recombinant reproducible genetic packets that do not bind to non-APC with an ApC and recover those that bind to the APC, where the retrievable reproducible genetic packets are capable of specifically binding to APC. In a further embodiment, the invention provides methods for evolving a vaccine delivery vehicle, genetic vaccine vector or component of a vector to obtain a delivery vehicle or optimized component to obtain a delivery vehicle or optimized release component that has or confers to a vector containing a component, a greater ability to enter a target cell by: (1) recombining at least the first and second forms of a nucleic acid encoding an invasin polypeptide, where the first and second forms differ from one another yes in two or more nucleotides, to produce a library of recombinant invasin nucleic acids; (2) producing a recombinant bacteriophage library, each of which has on the surface of the bacteriophage a fusion polypeptide encoded by a chimeric gene comprising a recombinant invasin nucleic acid operably linked to a polynucleotide encoding a presentation polypeptide; (3) contacting the library of the rectal bacteriophage with the target cell population; (4) removing the unbound phage and the phage that bound to the target surface; and (5) recovering the phage that is present within the target cells, where the recovered phages are rich in the phage that has greater capacity to enter the target cells. In some embodiments, optimized recombinant gene vaccine vectors, delivery vehicles, or optimized vector components obtained using those methods exhibit better ability to enter a cell presenting antigens. These methods may involve washing the cells after the transfection step to remove the vectors that do not enter an antigen-presenting cell; culturing the cells for a predetermined time after transfection; lyse the cells that present antigens; and isolate the vector of the genetic vaccine optimized from the used cell. Antigen-presenting cells containing optimized recombinant genetic vaccine vectors can be identified, for example, by detecting the expression of a marker gene that is included in the vectors. In some embodiments, the gene vaccine vector comprises a nucleotide sequence encoding an immunogenic antigen, and optimized recombinant gene vaccine vectors are identified: transfecting individual members of a library in separate cultures of antigen-presenting cells; or by culturing APC transfected with T-lymphocytes obtained from the same individual as APC; and identify transfected APC cultures which are capable of inducing a T lymphocyte response, the lymphocyte response in these methods can be selected from the group consisting of an increase in T lymphocyte proliferation, increased cytolytic activity mediated by T lymphocytes. against a target cell and the increase in cytosine production. As an example, the vector of the genetic vaccine may be capable of inducing a TH1 response according to what is evidenced by the transfected APCs that induce a response of the T lymphocytes that implies one or more of the proliferation, production of IL-2 and production of interferon? Additional modalities of these methods involve the use of gene vaccine vectors or delivery vehicles that include a nucleotide sequence that codes for an antigen.; optimized recombinant vaccine vectors can be identified: by injecting the library of the recombinant genetic vaccine vectors in a test animal;
obtaining lymphatic cells (e.g., dendritic cells) from the test animal; and recovering recombinant genetic vaccine vectors from lymphatic cells, where recovered recombinant genetic vaccine vectors exhibit better ability to enter lymphatic cells. In some embodiments, the antigen is a cell surface antigen, and before isolating the optimized recombinant gene vaccine vectors, the cells containing an optimized recombinant vector are purified to bind to an affinity reagent which selectively binds to the cell surface antigen. The invention also provides methods for evolving a vaccine delivery vehicle derived from a bacteriophage to obtain a delivery vehicle that has a greater capacity to enter a target cell. These methods involve the steps of: (1) recombining at least one first and second forms of a nucleic acid encoding an invasin polypeptide, wherein the first and second forms differ from each other in two or more nucleotides, to produce a library of recombinant invasin nucleic acids;
(2) producing a recombinant bacteriophage library, each of which displays on the surface of the bacteriophage a fusion polypeptide encoded by a chimeric gene comprising a recombinant invacinate nucleic acid operably linked to a polynucleotide that encodes a presentation; (3) contacting the recombinant bacteriophage library with a population of target cells; (4) removing the unbound phage and the phage that bound to the surface of the target cells; and (5) recovering the phage that is present within the target cells, where the recovered phage is rich in phage that have a greater capacity to enter the target cells. Again, if further optimization is desired, the methods may further include the steps of: (6) recombining a nucleic acid comprising at least one recombinant invasin nucleic acid obtained from a bacteriophage which is recovered from a target cell with a set Additional polynucleotides to produce an additional library of recombinant invasin polynucleotides; (7) producing an additional library of recombinant bacteriophage, each of which has on the surface of the bacteriophage a fusion polypeptide encoded by a chimeric gene comprising a recombinant invasin nucleic acid operably linked to a polynucleotide encoding a presentation; (8) contact the recombinant bacteriophage library with a population of cells .7
objective; (9) removing the unbound phage and the phage that bound to the surface of the target cells; and (10) recovering the phage that is present within the target cells and (11) repeating (6) through (10), as necessary, to obtain an additional optimized recombinant release vehicle which also exhibits enhanced ability to enter the target cells. In some embodiments, methods for evolving a vaccine delivery vehicle derived from a bacteriophage to obtain a delivery vehicle that has a greater ability to enter a target cell may include the additional steps of: (12) inserting into the delivery vehicle recombinant optimized a polynucleotide which encodes an antigen of interest, wherein the antigen of interest is expressed as a polypeptide function comprising a second polypeptide of presentation; (13) administering the delivery vehicle to a test animal; and (14) determining whether the test vehicle is capable of inducing a CTL response in the test animal. Alternatively, the following steps may be employed: (12) inserting into the optimized recombinant release carrier a polynucleotide which codes for an antigen of interest, wherein the antigen of interest is expressed as a fusion polypeptide which comprises a second polypeptide of presentation; (13) administering the delivery vehicle to a test animal; and (14) determining whether the delivery vehicle is capable of inducing neutralizing antibodies against a pathogen comprising an antigen of interest. An example of a target cell of interest for those methods is an antigen-presenting cell.
BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 illustrates a strategy for obtaining and using nucleic acid binding proteins that facilitate the entry of genetic vaccines, in particular, naked DNA, into target cells. The members of a library obtained by reloading the DNA are linked to a coding region of the M13 VII protein, so that a fusion protein is presented on the surface of the payment particles. The phage that efficiently enters the desired target tissue is identified, and the fusion protein is then used to coat the genetic vaccine nucleic acid. Figure 2 illustrates a strategy for separating M13 libraries for the desired direction of various tissues. The particularly illustrated example relates to the separation for improved oral delivery, but the same principle applies to libraries given by other means, including intravenous, intramuscular, intradermal, anal, vaginal or topically. After being released to a test animal, the M13 phage is recovered from the tissue of interest. The procedure can be repeated to obtain additional optimization. Figure 13 is an alignment of the nucleotide sequences encoding bacterial enterotoxins from two Escheri chia coli strains and cholera toxin B. The nucleotide sequences for enterotoxin B of E are shown. coli (SEQ ID NO: 1), enterotoxin B of E coli. (swine) (SEQ ID NO: 2), and subunit B of Cholera toxin (SEQ ID NO: 3). Figure A and Figure 4B show a protocol for the generation and transfection of human dendritic cells. Figure 4A shows the phenotype of freshly isolated monocytes (left) and cultured dendritic cells obtained by culturing blood monocytes in the presence of IL-4 and GM-CSF for seven days. Figure 4B shows a flow cytometry analysis of cultured dendritic cells after transfection by a plasmid encoding GFP.
DETAILED DESCRIPTION
Definitions The term "cytokine" includes, for example, interleukins, interferons, chemokines, hematopoietic growth factors, tumor necrosis factors, and transformation growth factors. In general, these are low molecular weight proteins that regulate the maturation, activation, proliferation and differentiation of the cells of the immune system. The term "separation" describes, in general, a process that identifies optimal antigens. Several properties of the antigen can be used in the selection and separation, including antigen expression, synthesis, stability, immunogenicity and presence of epitopes of several related antigens. Selection is a form of separation in which identification and physical separation are achieved simultaneously by expression of the selection marker, which, in some circumstances, allows the cells expressing the marker to survive while the other cells die ( or vice versa) . The "separation or selection" markers include, for example, luciferase, beta-galactosidase and green fluorescent protein.The selection markers include drug and toxin resistance genes, and the like.Due to limitations in the study of immune responses In these studies, antigens are first introduced into test animals, and immune responses are subsequently studied by analyzing the protective immune responses or by studying the quality or resistance of the immune responses. induced immune response using lymphoid cells derived from immunized animals.Although spontaneous selection can and do occur in the course of natural evolution, in the methods of the present selection it is effected by man.An "exogenous DNA segment", "heterologous sequence" "or a" heterologous nucleic acid "as used herein, is one that originates from a source external to the particular host cell, or, * if it is from the same source, is modified from an original form. Thus, a heterologous gene in a host cell includes a gene that is endogenous to the particular host cell, but that has been modified. The modification of a heterologous sequence in the applications described here typically occurs through the use of DNA entrainment. In this way, the terms still refer to a segment of DNA which is external or heterologous to the cell, or homologous to the cell but at a position within the nucleic acid of the host cell in which the element is not found in an ordinary manner . The exogenous DNA segments are expressed to produce exogenous polypeptides. The term "gene" is used herein broadly to refer to any DNA segment associated with a biological function. In this way, the genes include the coding sequences and / or the regulatory sequences required for their expression. Genes also include unexpressed DNA segments that, for example, form recognition sequences for other proteins. Genes can be obtained from a variety of resources, including cloning a source of interest or synthesizing from information from known or predicted sequences, and can include sequences designed to have desired parameters. The term "isolated", when applied to a nucleic acid or protein, denotes that the nucleic acid or protein is essentially free of other cellular components with which it is associated in the natural state. This is preferably in a homogeneous state although it may be in dry form or in an aqueous solution. Purity and homogeneity are typically determined using analytical chemistry techniques such as polyacrylamide gel electrophoresis or high performance liquid chromatography. A protein which is the predominant species present in a preparation is substantially purified. In particular, an isolated gene is separated from the open reading frames that flank the gene and codes for a protein other than the gene of interest. The term "purified" denotes that the protein nucleic acid essentially gives rise to a band in an electrophoretic gel. Particularly, this means that the nucleic acid or protein is at least about 50% pure, more preferably at least about 85% pure, and even more preferably at least about 99% pure. The term "natural" is used to describe an object that can be found in nature that is distinguished from that artificially produced by man. For example, a polypeptide or polynucleotide sequence that is present in an organism
(including viruses, bacteria, protozoa, insects, plants or mammalian tissue) that can be isolated from a natural source and that has not been intentionally modified by man in the laboratory is natural.
The term "nucleic acid" refers to deoxyribonucleotides or ribonucleotides and polymers thereof in the form of a single strand or double strand. Unless specifically limited, the term encompasses nucleic acids that contain known analogs of natural nucleotides which have binding properties similar to those of the reference nucleic acid and are metabolized in a manner similar to natural nucleotides. Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (eg, degenerate codon substitutions) and compntary sequences as well as the explicitly indicated sequence. Specifically, degenerate codon substitutions can be achieved by generating sequences in which the third position of one or more of (or all) of the selected codons is substituted with mixed base residues and / or deoxyinosine (Batzer et al. (1991) Nucl. c Acid Res. 19: 5081; Ohtska et al. (1985) J. Biol. Chem. 260: 2605-2608; Cassol et al. (1992); Rossolini et al. (1994) Mol. Cell. Probes 8:91 -98). The term "nucleic acid" is used interchangeably herein with a gene, cDNA, mRNA encoded by a gene.
"Nucleic acid derivative of a gene" refers to a nucleic acid from which the gene, or a subsequence thereof, has finally served as a standard. Thus, an mRNA, a cDNA transcribed in reverse manner from an mRNA, an RNA transcribed from that cDNA, a DNA amplified from the cDNA, and a RNA transcribed from the amplified DNA, etc., are all derived from the gene and the detection of such derivative products is indicative of the presence and / or abundance of the original gene and / or the transcript of the gene in a sample. A nucleic acid is "operably linked" when placed in a functional relationship with another nucleic acid sequence. For example, a promoter or amplifier is operably linked to a coding sequence if it increases the transcription of the coding sequence. Ligation operatively means that the DNA sequences that are ligated are typically contiguous and, when necessary, bind two protein coding regions, contiguous and in the reading frame. However, since the amplifiers generally operate when several kilobases are separated from the promoter and the intronic sequences can be of varying lengths, some polynucleotide ents may be operably linked but not contiguous.
A specific binding affinity between two molecules, for example, a ligand and a receptor, means a preferential binding of one molecule by another in a mixture of molecules. The binding of the molecules can be considered specific if the binding affinity is about 1 × 10 4 M "1 to about 1 × 10 6 M 1 or greater.The term" recombinant "when used with reference to an indica cell that the cell reproduces heterologous nucleic acid, or expresses a peptide or protein encoded by a heterologous nucleic acid.The recombinant cells may contain genes that are not found within the native (non-recombinant) form of the cell.The recombinant cells may also contain genes found in the This is the native form of the cell where the genes are modified and reintroduced into the cell by artificial means.The term also encompasses cells that contain an endogenous nucleic acid to the cell that has been modified without removing the nucleic acid from the cell; include those obtained by gene replacement, site-specific mutation, and related techniques A "recombinant expression cassette" or simply an "expression cassette" is a nucleic acid construct, generated recombinantly or synthetically, with the elements of the nucleic acid that are capable of affecting the expression of a structural gene in hosts compatible with such sequences. Expression cassettes include at least promoters and optionally, transcription termination signals. Typically, the recombinant expression cassette includes a nucleic acid to be transcribed (eg, a nucleic acid encoding a desired polypeptide), and a promoter. Additional factors necessary or helpful in effecting the expression may also be used as described herein. For example, an expression cassette may also include nucleotide sequences that encode a signal sequence that directs the secretion of an expressed protein from the host cell. Transcription termination signals, amplifiers, and other nucleic acid sequences that influence gene expression can also be included in an expression cassette. A "multivalent antigenic polypeptide" or a
"Recombinant multivalent antigenic polypeptide" is an unnatural polypeptide that includes amino acid sequences plus an original polypeptide, an original polypeptide which is typically a natural polypeptide. At least some of the regions of different amino acid sequences constitute epitopes that are recognized by antibodies found in a mammal that has been injected with the original polypeptide. The original polypeptides from which the different epitopes are derived are usually homologous (ie, having the same or similar structure and / or function), and are often different isolates, serotypes, strains, species, organisms or different disease states, for example. The terms "identical" or percent of
"identity", in the context of two or more nucleic acid or polypeptide sequences, refers to two or more sequences or subsequences that are the same or have a specific percentage of amino acid residues or nucleotides that are the same, when compared and align for maximum correspondence, as measured using one of the following sequence comparison algorithms or by visual inspection. The phrase "substantially identical", in the context of two nucleic acids or polypeptides, refers to two or more sequences or subsequences having at least 60%, preferably 80%, more preferably 90-95% identity of nucleotides or amino acid residues, when compared and aligned for maximum correspondence, as measured using one of the following sequence comparison algorithms or by visual inspection. Preferably, the substantial identity exists over a region of the sequence that is at least about 50 residues in length, more preferably over a region of at least about 100 residues, and most preferably the sequences are substantially identical over at least about 150 residues. In some embodiments, the sequences are substantially identical throughout the coding regions. For comparison of the sequence, typically a sequence acts as a reference sequence with which the test sequences are compared. When a sequence comparison algorithm is used, the test and reference sequences are fed to a computer, after which the coordinates are designated, if necessary, and the program parameters of the sequence algorithm are designated. The sequence comparison algorithm then calculates the percent identity of the sequence for the test sequence relative to the reference sequence, based on the designated program parameters. The optimal alignment of the sequences for comparison can be conducted, for example, by the local homology algorithm of Smith & Waterman, Adv. Appl. Ma thf 2: 482 (1981), by the homology alignment algorithm of Needleman & unsch, J. Mol. Biol. 48: 443 (1970), by the search for the similarity method of Pearson & Lipman, Proc. Na ti. Acad. Sci. USA 85: 2444 (1988), computerized implementations of those algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Package, Genetics Computer Group, 575 Science Dr., Madison, Wl) or by visual inspection (see in general Ausubel et al., Infra). An example of an algorithm that is suitable for determining the percent identity of the sequence and the similarity of the sequence is the BLAST algorithm, which is described in Ailtschul et al. , J. Mol. Biol. 215: 403-410 (1990). The programs and programming systems to carry out the BLAST analyzes are public domain and are available through the Center
National Biotechnology Information
(http://www.ncbi.nlm.nih.gov/). This algorithm involves first identifying high-grade sequence pairs (HSP) by identifying short-term words W in the sequence investigated, which are equal or satisfy some threshold qualification of positive value T when they are aligned with a word of the same length in a sequence of the database. T is known as the qualification threshold of the neighboring word (Alschul et al., Supra). It's right from the initial neighbor word acts as seed to start-searches to find larger HSPs that contain them. Word hits then extend in both directions along each sequence so that the cumulative alignment rating can be increased. The cumulative scores are calculated using, for nucleotide sequences, the M parameters (reward rating for a similar residue pair).; whenever it is > 0) and N (penalty rating for different residuals, provided it is <0). For amino acid sequences, a rating matrix is used to calculate the cumulative score. The extension of word hits in each direction stops when: the cumulative alignment qualification falls far from the amount X of its maximum value reached; the cumulative rating tends to zero or less, due to the accumulation of one or more alignments of negative rating residues; or at the end of which any sequence has been reached. The parameters of the BLAST algorithm W, T and X determine the sensitivity and speed of alignment. The BLAST program
(for nucleotide sequences) uses as default errors a word length (W) of 11, an expectation (E) of 10, a cut of 100, M = 5, N = -4, and a comparison of both strands. For amino acid sequences, the BLASTP program uses as a deflector values a word length (W) of 3, an expectation (E) of 10, and the qualification matrix BLOSUM62 (see Henikoff &Henikoff (1989) Proc. Na ti Acad. Sci. USA 89: 10915). In addition to calculating the percent identity of the sequence, the BLAST algorithm also performs a statistical analysis of the similarity between the two sequences (see, for example, Karlin &Altschul (1993) Proc. Na t '1. Acad. Sci. USA 90: 5873-5787). One measure of the similarity provided by the BLAST algorithm is the smallest sum probability (P (N)) which provides an indication of the probability of a similarity occurring between two nucleotide or amino acid sequences. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid with the reference nucleic acid is less than about 0.1, more preferably less than about 0.01. , more preferably less than about 0.001.
Another indication that the two nucleic acid sequences are substantially identical is that the two molecules hybridize to each other under stringent conditions. The phrase "specifically hybridizes to" refers to the binding, duplexing, or hybridization of only one molecule to a particular nucleotide sequence under stringent conditions when that sequence is present in a complex (e.g., cellular total) mixture of DNA or RNA "Substantial binding" refers to the complementary hybridization between a nucleic acid probe and a target nucleic acid and encompasses minor differences that can be accommodated by reducing the severity of the hybridization medium to achieve the desired detection of the target polynucleotide sequence. "Strict hybridization conditions" and "stringent hybridization washing conditions" in the context of nucleic acid hybridization experiments such as Southern and Northern hybridizations depend on the sequence, and are different under different environmental parameters. Longer sequences hybridize specifically at higher temperatures. An extensive guide for nucleic acid hybridization is found in Tijssen (1993) Laboratory Techniques in Biochemistry and Molecular Biology - Hybridization with Acid Probes, Nucleic Part I Chapter 2"General View of the Principles of Hybridization and Strategy Testing Nucleic Acid Probes ", Elsevier, New York. Generally, the highly stringent hybridization and washing conditions are selected such that they are about 5 ° C lower than the thermal melting temperature (Tm) for the specific sequence at a defined ionic strength and pH. Typically, under "stringent conditions" a probe will hybridize to its target sequence, but not to other sequences. The Tm is the temperature (under defined ionic strength and pH) at which 50% of the target sequence is hybridized to a perfectly matched probe or the like. The very strict conditions are selected so that they are equal to the Tm for a particular probe. An example of stringent hybridization conditions for the hybridization of complementary nucleic acids having more than 100 complementary residues on a Southern or Northern spot filter is 50% formamide with 1 mg of heparin at 42 ° C, with the hybridization being carried to Cape during the night. An example of highly stringent washing conditions in 0.15M NaCl at 72 ° C for about 15 minutes. An example of stringent washing conditions is a wash with 0.2x SSC at 65 ° C for 15 minutes (see, Sambrook, infra., For description of the SSC buffer). Frequently, a very strict washing is preceded by a little strict washing to remove the bottom signal of the probe. An example of moderately strict washing for a duplex of, for example, more than 100 nucleotides, is 1 x SSC at 45 ° C for 15 minutes. An example of a lax wash for a duplex of, for example, more than 100 nucleotides is 4-6x SSC at 40 ° C for 15 minutes. For short probes (eg, from about 10 to 50 nucleotides), stringent conditions typically involve salt concentrations of less than about 1.0 M Na + ion, typically a concentration of about 0.1 to 1.0 M Na + ion (or other salts). at pH 7.0 to 8.3, and the temperature is typically at least about 30 ° C. Strict conditions can also be achieved with the addition of stabilizing agents such as formamide. In general, a signal-to-noise ratio of 2x (or greater) greater than that observed for an unrelated probe in the particular hybridization assay indicates the detection of a specific hybridization. Nucleic acids that do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides they encode are substantially identical.
This occurs, for example, when a nucleic acid copy is created using the maximum codon degeneracy allowed by the genetic code. An additional indication that two nucleic acid sequences or polypeptides are substantially identical is that the polypeptide encoded by the first nucleic acid reacts immunologically cross-linked with, or specifically binds to, the polypeptide encoded by the second nucleic acid. Thus, the polypeptide is typically, substantially identical to a second polypeptide, for example, where the two peptides differ only by conservative substitutions. The phrase "that binds specifically" (or selectively) to an antibody "or" specifically (or selectively) immunoreactive with ", when referring to a protein or peptide, refers to a binding reaction which is determinant of the presence of the protein, or an epitope of the protein, in the presence of a heterogeneous population of protein and other biological products.Thus, under the designated immunoassay conditions, the specific antibodies bind to a particular protein and do not bind in a significant amount to other proteins present in the sample Antibodies directed against a multivalent antigenic polypeptide will generally bind to proteins from which one or more of the epitopes were obtained.Specific binding to an antibody under such conditions may require an antibody that be selected for its specificity by a particular protein.A variety of immunoassay formats can be used naysay to select antibodies specifically immunoreactive with a particular protein. For example, ELISA immunoassays in solid phase, spotting or Western immunoblotting, or immunohistochemistry are commonly used to select monoclonal antibodies specifically immunoreactive with a protein. See Harlow and Lane (1988) Antibodies, A Labora tory Manual, Cold Spring Harbor Publications, New York "Harlow and Lane"), for a description of the immunoassay formats and conditions that can be used to determine specific immunoreactivity. Typically a specific or selective reaction will be at least twice the signal or background noise and more typically more than 10 to 100 times the background. "Conservatively modified variations" of a particular polynucleotide sequence refers to these polynucleotides that encode identical or essentially identical amino acid sequences, or where the polynucleotide does not code for an amino acid sequence, for essentially identical sequences. Due to the generation of the genetic code, a large number of functionally identical nucleic acids encode - for any given polypeptide. For example, the codons CGU, CGC, CGA, CGG, AGA, and AGG all code for the amino acid arginine. Thus, at each position where an arginine is specified by a codon, the codon can be altered to any of the corresponding codons described without altering the encoded polypeptide. Such variations of the nucleic acid are "silent variations", which are a kind of "conservatively modified variations". Each polynucleotide sequence described herein that codes for a polypeptide also describes every possible silent variation, except where otherwise noted. One skilled in the art will recognize that each codon in a nucleic acid (except AUG, which is commonly the only codon for methionine) can be modified to produce a functionally identical molecule by standard techniques. Accordingly, each "silent variation" of a nucleic acid encoding a polypeptide is implicit in each described sequence.
In addition, one skilled in the art will recognize that substitutions, deletions or individual additions that alter, aggregate or delete a single amino acid or a small percentage of amino acids (typically less than 5%, more typically less than 1%) in a coded sequence are "conservatively modified variations", where the alterations result in the substitution of an amino acid with the chemically similar amino acid. The tables of conservative substitutions that provide functionally similar amino acids are known in the art. The following five groups each contain amino acids that are conservative substitutions with each other: Aliphatic: Glycine (G), Alanine (A), Valine (V), Leucine (L), Isoleucine (I); Aromatic: Phenylalanine (F), Tyrosine (Y), Tryptophan (W); Containing sulfur: Methionine (M), Cysteine (C); Basic: Arginine (R), Lysine (K), Histidine
(H); Acid: Aspartic acid (D), glutamic acid
(E), Asparagine (N), Glutamine (Q). Also see,
Creighton (1984) Proteins, W.H. Freeman and Company, for additional amino acid groupings. In addition, individual substitutions, deletions or additions that alter, or delete a single amino acid or a single percentage of amino acids in an encoded sequence are also "conservatively encoded variations." A "subsequence" refers to a nucleic acid or amino acid sequence that comprises a part of a longer sequence of nucleic acids or amino acids (e.g., polypeptide), respectively.
DESCRIPTION OF THE PREFERRED EMBODIMENTS The present invention provides reagents for facilitating the ability of a genetic vaccine to specifically bind to and enter a target cell or tissue of interest, and methods for obtaining such agents. In particular, the invention provides methods for obtaining binding peptides and delivery vehicles which, when used in conjunction with a genetic vaccine, increase the specificity of the genetic vaccine for a particular type of target cell. The methods are also useful for obtaining components of the genetic vaccine that can confer a desired targeting specificity when used in conjunction with a genetic vaccine vector.
A. Creation of Recombinant Libraries The invention involves creating recombinant libraries of polynucleotides that are then separated to identify those members of the library that exhibit a desired property. The recombinant libraries can be created using any of the methods. The substrate nucleic acids used for recombination may vary depending on the particular application. For example, where a polynucleotide encoding a nucleic acid binding domain or a ligand for a specific receptor of a cell is to be optimized, different forms of nucleic acids encode all or part of the nucleic acid binding domain or a ligand for a specific receptor of a cell are subjected to recombination. The methods require at least two variant forms of an initial substrate. The variant forms of the candidate substrates may show a substantial sequence or secondary structural similarity to each other, but must also differ in at least two positions. The initial diversity between the forms can be the result of a natural variation, for example, the different variant forms (homologous) are obtained from different individuals or members of an organism (including geographical variants) or constitute related sequences of the same organism ( for example, allelic variations). Alternatively, the initial diversity may be induced, for example, the second variant form may be generated by an error-prone transcript, such as an error-prone PCR or the use of a polymerase that lacks proven reading activity (see Liao (1990) Gene 88: 107-111), of the first variant form, or, by reproduction of the first form in a sepa or mutant (the mutant host cells are described in more detail below). The initial diversity between the substrates is generally increased in subsequent steps of recombination of the recursive sequence. Frequently, improvements are achieved after a round of recombination and selection. However, recursive sequence recombination can be employed to achieve even greater improvements in the desired property. The sequence recombination can be carried out in many formats and swaps of different formats, as described in detail below. These formats share some common principles. Recursive sequence recombination consists of successive recombination cycles to generate molecular diversity. That is, a family of nucleic acid molecules is created that show some sequence identity to each other but differ in the presence of mutations. In any given cycle, recombination may occur in vivo or intracellular or extracellular in vi tro. In addition, the diversity resulting from recombination can be increased in any cycle by applying the above mutagenesis methods (e.g., error prone PCR or cassette mutagenesis) to any of the substrates or products of recombination. In some cases, a new property or enhanced characteristic can be achieved after only a recombination cycle in vivo or in vi tro, such as when different variant forms of the sequence are used, such as homologs of different individuals or members of an individual, or sequences related to the same organism, such as allelic variations. In a preferred embodiment up to now, recombinant libraries are prepared using DNA entrainment. The entrainment and separation or selection can be used to "evolve" individual genes, complete plasmids or viruses, multiple gene sets, or even all genomes (Stemmer (1995) Bio / Technology 13: 549-553). Repeat cycles of recombination and separation / selection can be performed to further evolve the nucleic acids of interest. Such techniques do not require the extensive analysis and computation required by conventional methods to design polypeptides. Trawling allows the recombination of large numbers of mutations in a minimum number of selection cycles, in contrast to the traditional pair recombination events. Thus, the sequence recombination techniques described here provide additional advantages since they provide recombination between any or all of those mutations, thus providing a faster way to explore the manner in which different combinations of mutations can affect a desired result. In some cases, however, structural and / or functional information is available which, although not required for sequence recombination, provides opportunities for modification of the technique. Exemplary formats and examples of sequence recombination, sometimes referred to as DNA drag, evolution or molecular reproduction, have been described by the inventors and co-workers herein by U.S. patent applications. copending Serial No. 08 / 198,431, filed on February 17, 1994, Serial No. PCT / US95 / 02126, filed on February 17, 1995, Serial No. 08 / 425,684, filed on April 18, 1995, No. of Series 08 / 537,874, filed on October 30, 1995, Serial No. 08 / 564,955, filed on November 30, 1995, Serial No. 08 / 621,859, filed on March 25, 1996, Serial No. 08 / 621,430 , filed March 25, 1996, Serial No. PCT / US96 / 05480, filed on April 18, 1996, Serial No. 08 / 650,400, filed on May 20, 1996, Serial No. 08 / 675,502, filed at July 3, 1996, Serial No. 08 / 721,824, filed September 27, 1996, Serial No. PCT / US97 / 17300, filed September 26, 1997, Serial No. PCT / US97 / 24239, filed in December 17, 1997; Stemmer, Sciencie 270: 1510 (1995); Stemmer et al., Gene 164: 49-53 (1995); Stemmer, Bio / Technology 13: 549-553 (1995); Stemmer, Proc. Nati Acad. Sci. U.S.A. 91: 10747-10751 (1994); Stemmer, Nature 370: 389-391 (1994); Crameri et al., Nature Medicine 2 (1): 1-3 (1996); Crameri et al. Nature Biotechnology 14: 315-319 (1996), each of which is incorporated herein by reference in its entirety for all purposes. Other methods for obtaining recombinant polynucleotides and / or for obtaining diversity in the nucleic acids used as the substrates for DNA entrainment, include homologous recombination (PCT / US98 / 05223: Publ.No W098 / 42727); mutagenesis 4
directed to the oligonucleotide (for a review see, Smith, Ann, Rev. Genet, 19: 423-462 (1985), Botstein and Shortle, Science 229: 1193-1201 (1985); Carter, Biochem. J. 237: 1- 7 (1986); Kunkel, "The efficiency of oligonucleotide-directed mutagenesis" in Nucleic acids &Molecular Biology, Eckstein and Lilley, eds., Springer Verlag, Berlin (1987)). Included among these methods is oligonucleotide-directed mutagenesis (Zoller and Smith, Nuci, Acids Res. 10: 6487-6500 (1982), Methods in Enzymol, 100: 468-500 (1983), and Methods in Enzymol. -350 (1987)) mutagenesis of phosphothiated DNA (Taylor et al., Nucí Acids Res. 13: 8749-8764 (1985); Taylor et al., Nucí Acids Res. 13: 8765-8787 (1985); Nakamaye and Eckstein, Nucí Acids Res. 14: 9679-9698 (1986), Sayers et al., Nucí Acids Res. 16: 791-802 (1988), Sayers et al., Nucí Acids Res 16: 803 -814 (1988)), mutagenesis using uracil-containing standards (Kunkel, Proc. Nat'l. Acad. Sci. USA 82: 488-492 (1985) and Kunkel et al., Methods in Enzymol. 154: 367-382 )); mutagenesis using separate duplex DNA (Kramer et al., New Acids Res. 12: 9441-9456 (1984); Kramer and Fritz, Methods in Enzymol., 154: 350-367 (1987); Kramer et al., Nuci. Res. 16: 7207 (1988)); and Fritz et al_. , Nucí. Acids Res 16: 6987-6999. Additional and suitable methods include repair of point mating mismatch (Kramer et al., Cell 38: 879-887 (1984)), mutagenesis using efficient host strains under repair (Carter et al., Nucí Acids Res. 13: 4431 -4443 (1985); ~ Carter, Methods in Enzymol 154: 382-403 (1987)), deletion mutagenesis (Eghtedarzadeh and Henikoff, Nuci Acids Res. 14: 5115 (1986)), restriction-selection and restriction- purification (Wells et al., Phil. Trans. R. Soc. Lond. A 317: 415-423 (1986), mutagenesis by total genetic synthesis (Nambiar et al., Science 223: 1299-1301 (1984); Sakamar et al. Khorana, Nucí, Acids Res. 14: 6361-6372 (1988), Wells et al., Gene 34: 315-323 (1985), and Grundstr? M et al., Nucí. Acids Res. 13: 3305-3316 ( 1985). Equipment for mutagenesis is commercially available, (e.g., Bio-Rad, Amersham International, Anglian Biotechnology).
B. Separation Methods A recombination cycle usually followed by at least one separation or selection cycle for molecules having a desired property or characteristic. If a recombination cycle is carried out in vi tro, the products of recombination, i.e., the recombinant segments, are sometimes introduced into cells before the separation step. The recombinant segments can also be ligated to an appropriate vector or other regulatory sequences before separation. Alternatively, the recombination products generated in vitro are sometimes packaged as viruses before separation. If recombination is carried out in vivo, the products of recombination can sometimes be separated into the cells in which recombination occurred. In other applications, the recombinant segments are extracted from the cells, and optionally packaged as a virus, before separation. The nature of the separation or selection depends on what property or characteristic is to be acquired or the property or characteristic for which improvement is sought, and many examples are discussed below. It is usually not necessary to understand the molecular basis by which the recombination products
(recombinant segments) have acquired new or improved properties or characteristics in relation to the initial substrates. For example, a gene vaccine vector can have many component sequences, each of which has a different intended role (eg, coding sequence, regulatory sequences, targeting sequences, stability-conferring sequences, immunomodulatory sequences, sequences that affect the presentation of antigens, and sequences that affect the integration). Each of these component sequences can be varied and recombined simultaneously. The separation / selection can then be made, for example, for recombinant segments that have a higher episomal maintenance in a target cell without the need to attribute such improvement to any of the individual component sequences of the vector. Depending on the particular separation protocol used for a desired property, the initial rounds of separation can sometimes be performed on bacterial cells due to high transfection efficiencies and ease of culture. The final rounds, and other types of separation that are not sensitive to separation in bacterial cells, are carried out in a mammalian cell to optimize the recombinant elements to be used in an environment close to the intended use. The final rounds of separation can be carried out in the precise cell type of the intended use (eg, human antigen-presenting cell). In some cases, this cell can be obtained from a patient to be treated with a view, for example, to reduce the immunogenicity problems in this patient.
The separation or selection step identifies a subpopulation of recombinant segments that have evolved towards the acquisition of a desired new property or improved properties useful in genetic vaccination. Depending on the separation, the recombinant segments can be identified as components of cells, virus components or in free form. More than one round of separation or selection can be made before each round of recombination. If a further improvement in a property is desired, at least one and usually a collection of recombinant segments surviving a first round of separation / selection are subjected to an additional round of recombination. These recombinant segments can be recombined with each other or with exogenous segments that represent the original substrate or additional variants thereof. Again, recombination can proceed in vi tro or in vivo. If the previous separation step identifies the desired recombinant segments as components of the cells, the components can be subjected to further recombination in vivo, or they can be subjected to further recombination in vi tro c can be isolated before making a round of recombination in vi tro. On the contrary, if the previous separation step identifies that the desired recombinant segments are in naked form or as components of virus, those segments can be introduced into cells to effect a round of recombination in vivo. The second round of recombination, no matter how it is carried out, generates additional recombinant segments which encompass the additional diversity that is present in the recombinant segments resulting from the previous rounds. The second round of recombination can be followed by a fourth round of separation / selection according to the principles discussed above for the first round. The stiffness of the separation / selection can be increased between rounds. Also, the nature of the separation and the property being separated may vary between rounds if an improvement in more than one property is desired or if more than one new desired property is being acquired. Additional rounds of recombination and separation can then be carried out until the recombinant segments have evolved sufficiently to acquire the desired new or improved property or function. Various separation methods for particular applications are described here. In several cases, separation involves expressing the recombinant peptides or polypeptides encoded by the recombinant polynucleotides of the library as fusions with a protein that is presented on the surface of a reproducible genetic package. For example, phage display can be used. See, for example, Cwirla et al., Proc. Nati Acad. Sci. USA 87: 6378-6382 (1990); Devlin et al., Science 249: 404-406 (1990), Scott & Smíth, Science 249: 386-388 (1990); Ladner et al., US 5,571,698. Other reproducible genetic packages include, for example, bacteria, eukaryotic viruses, yeasts and spores. The genetic packages most frequently used to present the library are bacteriophages, particularly filamentous phages, and especially phage M13, Fd and Fl. The majority of the work has involved inserting libraries that encode polypeptides to be presented in either the gilí or gVIII of that phage forming a fusion protein. See, for example, Dower, WO 91/19818; Devlin, WO 91/18989; MacCafferty, WO 92/01047 (gen III); Huse, WO 92/062074; Kang, WO 92/18619 (gen VIII). Such fusion protein comprises a sequence usual, but not necessarily, of the phage coat protein, a polypeptide to be presented and any of the gene III protein or gene VIII or fragment thereof. Exogenous coding sequences are often inserted at or near the N-terminus of gene III or gene VIII although other insertion sites are possible. Eukaryotic viruses can be used to present polypeptides in an analogous manner. For example, the presentation of human heregulin fused to gp70 of Moloney murine leukemia virus has been reported by Han et al., proc. Nati Acad. Sci. USA 92: 9747-9751 (1995). Spores can also be used as reproducible genetic packages. In this case, the polypeptides are presented from the outer surface of the spore. For example, it has been reported that B. subtilis spores are adequate. The sequences of the coating proteins of these spores are provided by Donovan et al., J. Mol. Biol. 196, 1-10 (1987). Cells can also be used as reproducible genetic packages. The polypeptides to be presented are inserted into a gene that codes for a cellular protein that is expressed on the surface of the cells. Bacterial cells include Salmonella typhimurium, Bacillus subtilis, Pseudomonas aeruginosa, Vibrio cholearae, Klebsiella pneumonia, Neisseria gonorrhoeae, Neisseria meningitidis, Bacteroides nodosus, Moraxella bovis, and Escherichia coli is especially preferred. The details of the outer surface proteins are discussed by Ladner et al., US 5,571,698 and references cited therein. For example, the lamB protein of E. coli is adequate. A basic concept of presentation methods that utilize phage or other reproducible genetic package is the establishment of a physical association between the DNA encoding a polypeptide to be separated and the polypeptide. This physical association is provided by the reproducible genetic package, which presents a polypeptide as part of a capsule enclosing the phage genome or other package, where the polypeptide is encoded by the genome. The establishment of a physical association between the polypeptides and their genetic material allows simultaneous mass separation of a very large number of phages containing different polypeptides. The phage presenting a polypeptide with affinity for an objective, for example, a receptor, binds to the target and those phages are enriched by affinity separation with the target. The identity of the polypeptides presented by those phages can be determined from their respective genomes. Using those methods a peptide identified by having a binding affinity with a desired target can then be synthesized in bulk by conventional means, or the polynucleotide encoding the peptide or polypeptide can be used as part of a genetic vaccine. The recombinant t-nucleic acid libraries that are obtained by the methods described herein are selected to identify those DNA segments that have a property which is desirable for genetic vaccination. The particular separation test employed will vary, as described below, depending on the particular property for which the improvement is sought. Typically, the entrained nucleic acid library is introduced into the cells prior to separation. If the DNA entrainment format is used in vivo, the library of the generated recombinant DNA segments already exists in a cell. If the recombination of the sequence is carried out in vitro, the recombinant library is preferably introduced into the desired cell type before separation / selection. Members of the recombinant library can be linked to an episome or virus before introduction or can be introduced directly. A wide variety of cell types can be used as receptors for evolved genes. Cells of particular interest include many types of bacterial cells that are used to release vaccines or vaccine antigens (Courvalin et al (1995) CR Acad. Sci. III 18: 1207-12), both gram negative and gram positive, such such as Salmonellas (Attridge et al. (1997) Vaccine 15: 155-62), clostridium (Fox et al. (1996) Gene Ther 3: 173-8), lactobacillus, Shigella (Sizemore et al. (1995) Science 270 : 299- 02, E. coli, streptococci (Oggioni and Pozzi (1996) Gene 169: 85-90), as well as mammalian cells, including human cells. In some embodiments of the invention, the library is amplified in a first host, and then recovered from that host and introduced into a second host more sensitive to expression, selection, separation, or any other desirable parameter. The manner in which the library is introduced into the cell type depends on the absorption characteristics of cell-type DNA, for example, having viral receptors, being able to conjugate, or being naturally competent. If the cell type is not susceptible to natural or chemically induced competition, but is sensitive to electroporation, electroporation would usually be employed. If the cell type is not susceptible to electroporation, biolistics can also be used. The biolistic PDS-1000 Genetic Cannon (Biorad, Hercules, CA) uses helium pressure to accelerate gold or tungsten microcarriers coated with DNA to target cells. The process is applicable to a wide range of tissues, including plants, bacteria, fungi, algae, intact animal tissues, tissue culture cells and animal embryos. The release of electronic pulses can be employed, which is essentially an electroporation format released for living tissues in animals and patients (Zhao, Advanced Drug Delivery Reviews 17: 257-262
[1995]). Novel methods for labeling competent cells are described in International Patent Application PCT / US97 / 04494 (Publ. No. W097 / 35957). After the introduction of the recombinant DNA gene library, the cells are optionally programmed to allow the expression of the genes to occur. In many assays, means are needed to identify cells that contain a particular vector. Vectors of genetic vaccines of all types may include a selectable gene marker. Under selective conditions, only those cells that express the selectable marker will survive. Examples of suitable markers include, the dihydrofolate reductase (DHFR) gene, the thymidine kinase (TK) gene or prokaryotic genes that confer drug resistance, gpt (xanthin-guanine phosphostibosyltransferase), which can be selected by acid mycophenolic; neo (neomycin phosphotransferase), which can be selected with G418, hygromycin or puromycin; and DHFR (dihydrofolate reductase), which can be selected with methotrexate (Mulligan &Berg (1981) Proc. Nat'l. Acad Sci. USA 78: 2072; Southern &Berg (1982) J. Mol. Appl. Genet 1: 327). As an alternative, or in addition to, a selectable marker, a genetic vaccine vector may include a selectable marker which, when expressed, confers to a cell containing the vector an easily identifiable genotype. For example, gene encoding a cell surface antigen that is not normally present on the appropriate host cell. The detection means can be, for example, an antibody or another ligand that is specifically to the cell surface antigen. Examples of suitable cell surface antigens include any CD antigen (set of differentiation) (CD1 to CD163) of a species other than the host cell that has not been recognized by host-specific antibodies. Other examples include the green fluorescent protein (GFP, see, for example, Chalfie et al (1994) Science 263: 802-805; Crameri et al (1996) Nature Biotechnol., 14: 315-319; Chalfie et al. (1995) Photochem, Photobiol, 62: 651-656, Olson et al. (1995) J.
Cell. Biol. 130: 639-650) and related antigens, several of which are commercially available.
1. Separation for Longevity or Translocation of the Vector to the Desired Fabric For certain applications, it is desirable to identify those vectors with greater longevity as DNA or to identify the vectors that end in distant tissues from the injection site. This can be achieved by administering to a mammal a population of recombinant genetic vaccine vectors by choosing the route of administration and, at several subsequent times, cutting the target tissue and recovering plasmid from the tissue by standard molecular biology procedures. The molecules in the recovered vector can be amplified in, for example, E. coli and / or by PCR in vi tro. PCR amplification may involve additional entrainment of the gene, after which the selected derivative population is used for readministration to the animals and further improvement of the vector. After several rounds of this procedure, the selected plasmids can be tested for their ability to express the antigen in the correct conformation under the same conditions in which the plasmid was selected in vivo.
Because the expression of the antigen is not part of the selection or separation process described above, not all vectors obtained are capable of expressing the desired antigen. To overcome this disadvantage, the invention provides methods for identifying a. those vectors in a population of genetic vaccine that exhibits not only the location and longevity in the desired tissue in the integrity of living DNA, but the retention of maximal antigenic expression (or expression of other genes such as cytosines, chemokines, accessory molecules) of the cell surface, MHC, and the like). The methods involve the identification in vi tro of cells that express the desired molecule using purified cells of the tissue of choice, under conditions that allow the recovery of very small numbers of cells and the quantitative selection of those with different levels of antigen expression, according to is desired Two embodiments of the invention are described, each of which utilizes a library of genetic vaccine vectors as a starting point. The goal of each method is to identify those plasmids that exhibit the desired biological properties in vivo. The recombinant library represents a population of vectors that differ in known ways (eg, a combined vector library of different functional modules), or has a randomly generated diversity generated by the insertion of random nucleocyte segments, or has been entrained in vivo to introduce low level mutations through all or part of the vectors.
(a) Selection of the antigen expression located on the cell surface. In a first embodiment, the method of the invention involves the selection of the expression of the antigen located on the cell surface. The antigen gene is designed in the plasmidic library of the vaccine so that it has a region of amino acids which are directed to the cell membrane. For example, the region can code for a hydrophobic segment of C-terminal amino acids which signal the binding of a terminal phosphoinositol-glycan (PIG) on the expressed protein and direct the protein to be expressed on the surface of the transfected cell. With an antigen that is naturally a soluble protein, this method will probably not affect the three-dimensional configuration of the protein in its designed fusion with a new C-terminus. With an antigen that is naturally a transmembrane protein (eg, a surface membrane protein or pathogenic viruses, bacteria, protozoa or tumor cell) there are at least two possibilities. First, the extracellular domain can be designed to merge with the C-terminal sequence to signal the link to the PIG. Second, the protein can be expressed in toto depending on the signaling of the host cell to efficiently direct it towards the cell surface. In most cases, the antigen for expression will have an endogenous PIG terminal bond (e.g., some pathogenic protozoan antigens). The vector library is released in vivo after an appropriate time interval tissues and / or cells are collected from various target sites in the animal. The cells can be purified from the tissue using standard cellular biological procedures, including the use of monoclonal antibodies reactive with the specific cell surface as affinity reagents. It is relatively feasible to purify epithelial cells isolated from mucosal sites where the epithelium could have been inoculated or muscle neoblasts. In some embodiments, a minimal physical purification is performed before analysis. It is sometimes desirable to identify and separate specific cell populations from various tissues, such as the vessel, liver, bone marrow, lymphatic organs and blood. Blood cells can be fractionated easily by FACS to separate B, CD4 + or CD8 + cells, dendritic cells, Langerhans cells, monocytes, and the like, using various fluorescent monoclonal and antibody reagents. Those cells expressing the antigen can be identified with a fluorescent monoclonal antibody specific for the C-terminal sequence on the linked PIG forms of the surface antigen. The analysis by FACS allows the quantitative evaluation of the level of expression of the correct form of the antigen on the cell population. Cells expressing the maximum level of antigen are classified and standard molecular biology methods are used to recover the vector of the plasmid DNA vaccine that confers this reactivity. An alternative procedure that allows the purification of those cells that express the antigen (and which may be useful before loading in a cell sorter, since the cells expressing the antigen may be a minority population very small), is to form rosettes or purify by screening the cells expressing surface antigens. The rosettes can be formed between the antigen expressing the cells and the erythrocytes carrying the antibody covalently coupled with the relevant antigen. These are easily purified by gravity sedimentation. Screening of the entire cell population on Petri dishes containing immobilized monoclonal antibody specific for the relevant antigen can also be used to remove undesirable cells. Cells expressing the conformational structure of the target antigen can be identified using specific conformationally dependent mononuclonal antibodies that are known to react specifically with the same structure that is expressed on the target pathogen. Because a monoclonal antibody can not define all aspects of the correct structure of the target antigen, the possibility of an antigen which reacts with a high affinity to the diagnostic antibody but does not produce the correct conformation according to what is defined by what in which the antigen is on the surface of the target pathogen or as secreted from the target pathogen. One way to minimize this possibility is to use several monoclonal antibodies, each of which is known to react with different conformational epitopes in the folded protein correctly, in the selection process. This can be achieved by means of a secondary FACS classification, for example. The enriched plasmid population that successfully expresses sufficient antigen in the correct body site for the desired time is then used as the initial population for another selection round., incorporating the gene drag to expand diversity. In this way, the biological activity selected by the plasmid from the tissues in the animals immunized by DNA vaccine is recovered. This method can also provide the best selected vectors expressing immune accessory molecules that one may wish to incorporate into DNA vaccine constructs. For example, if it is desired to express the accessory protein B7.1 or B7.2 in antigen-presenting cells (APC) (to promote successful penetration of the antigen to T cells) APC isolated from different tissues (in or different inoculation sites) using commercially available monoclonal antibodies that recognize functional B7 proteins.
(b) Selection of the expression of ajitigen / secreted ci tocxna / qvtimocins Another separation method is to identify the plasmids in a population of genetic vaccine vectors that are optimal for inducing the secretion of soluble proteins that can affect the quantitative and qualitative nature of an immune response produced. For example, vectors that are optimal for inducing the secretion of particular cytokines, growth factors and chemokines can be selected. The first step in these methods is to generate vectors containing the members of the library of the recombinant nucleic acids. These vectors can then be individually tested for their efficacy in vivo. The vector library is supplied to a test animal and, after a chosen time interval, tissue and / or cells are collected from various animal sites. The cells are purified from the tissue using standard cell biology procedures which often include the use of cell-specific surface reactive monoclonal antibodies as affinity reagents. As is the case for the cell surface antigens described above, the physical purification of separate cell populations can be carried out prior to the identification of the cells expressing the desired protein. For those studies, the target cells for the expression of cytokines will very usually be APC or B cells or T cells instead of muscle cells or epithelial cells. In such cases the separation by FACS by $ S established methods will be preferred to separate the different cell types. The different cell types described above can also be separated into relatively pure fractions using affinity separation, rosette formation or separation with magnetic beads with panels of existing monoclonal antibodies that are known to define the surface membrane phenotype of murine immune cells. The purified cells are grown on agar plates under conditions that maintain the viability of the cell. The cells that express
< Required conformational structures of the target antigen are identified using conformationally dependent monoclonal antibodies that are known to react specifically with the same structure expressed on the target pathogen. The release of the relevant soluble protein from the cells is detected by incubation with monoclonal antibody, followed by a secondary reagent that gives a macroscopic signal (gold position, color development, fluorescence, luminescence). Cells expressing the maximum level of antigen can be identified by visual inspection, the cell or cell colony is removed and standard molecular biology methods are used to recover the plasmid DNA vaccine vector conferring this reactivity. Alternatively, flow cytometry can be used to identify and select cells harboring plasmids that induce high levels of gene expression. The enriched plasmid population that successfully expresses enough soluble factor in the correct body site for the desired time is then used for the initial population for another round of selection, incorporating the gene letdown to expand diversity, if further improvement is desired. . In this way, the desired biological activity encoded by the plasmid from the tissues in immunized animals is recovered with DNA vaccine. Several monoclonal antibodies, each of which is known to react with different conformational epitopes in the cytokine, chemokine or correctly folded growth factor, can be used to confirm that the initial result of selection with a monoclonal antibody reagent is still maintained with the Different conformational epitopes are probed.
In some cases the primary probe for the conformational cytokine released from the cell / cell colony on agar could be a soluble domain of the cognate receptor. (c) Flow Cytometry Flow cytometry provides a means to efficiently analyze the functional properties of millions of individual cells. The cells are passed through a zone of illumination, where they are hit by a laser beam; scattered light and fluorescence are analyzed by detectors linked to a computer. Flow cytometry provides several advantages over other methods for analyzing cell populations. Thousands of cells per second can be used, with a high degree of accuracy and sensitivity. A punishment of cell populations allows the analysis of multiple parameters of each sample. The size of the cell, viability, and morphology can be analyzed without the need for staining. When stained and labeled antibodies are used, the content of DNA, cell surface and intracytoplasmic proteins can be analyzed, and the cell type, activation status, cell cycle stage, and apoptosis detected. Up to four colonies (ie, four separate antigens stained with different fluorescent labels) and light scattering characteristics can be analyzed simultaneously (four colors require two laser instruments, one laser instrument can analyze three colors). The level of expression of the different genes can be analyzed simultaneously, and importantly, cell separation or classification based on flow cytometry ("FACS classification") allows the selection of cells with the desired phenotypes. Most libraries of vector modules, including the promoter, amplifier, intron, episomal origin of reproduction, appearance of the level of expression of the antigen, origin of the bacterium and bacterial marker, can be assayed by flow cytometry to select cells from individual human tissue culture containing the recombinant nucleic acid sequences that have the greatest improvement in the desired property. Typically, the selection is for a high level of expression of a surface antigen or substitute marker protein, as outlined schematically in Error! Reference source not found. The set of the best individual sequences is recovered from the selected cells by classification or separation based on cytometries. An advantage of this method is that very large numbers (> 107) can be evaluated in a single-bottle experiment.
2. In Vitro Separation Methods Vectors of genetic vaccines and vector modules can be separated by improved vaccination properties using various in vitro testing methods that are known to those skilled in the art. For example, the genetic vaccines used can be tested for their effect on the induction of the proliferation of a particular type of lymphocyte of interest, for example, B cells, T cells, T cell lines, and T cell clones. of separation for improved adjuvant activity and immunostimulatory properties can be carried out using, for example, human or mouse cells. A library of genetic vaccine vectors (obtained from randomized dormant DNA or from vectors harboring genes coding for cytokines, costimulatory molecules, etc.) can be separated for the production of cytokines (eg, IL-2, IL-4, IL -5, IL-6, IL-10,
IL-12, IL-13, IL-15, IFN- ?, IFN-a) by B cells, cells
T, monocytes / macrophages, total human PBMC, or whole blood (diluted). Cytokines can be measured by ELISA or cytoplasmic cytokine staining and flow cytometry (single-cell analysis). On the basis of the profile of cytokine production, alterations in the capacity of the vectors can be separated to direct the differentiation of TH1 / TH2 (according to what is evidenced, for example, by changes in the ratios of IL-4 / IFN-? , IL-4 / IL-2, IL-5 / IFN- ?, IL-5 / IL-2, IL-13 / IFN- ?, IL-13 / IL-2). The induction of APC activation can be detected based on changes in the surface expression levels of activation antigens, such as B7-1 (CD80), B7-2 (CD86), MHC class I and II, CD14, CD23, and Fc receptors, and the like. In some embodiments, gene vaccine vectors are analyzed for their ability to induce T cell activation. More specifically, spleen cells from injected mice can be isolated and the ability of cytotoxic T lymphocytes to lyse target cells can be studied. infected autologous Spleen cells are reactivated with the specific antigen in vi tro. In addition, the differentiation of T cells is analyzed by measuring the proliferation of the TH1 cytokines (IL-2 / IFN-?) And TH2 (IL-4 and IL-5) by ELISA and directly in CD4 + T cells by staining the Cytoplasmic cytokine and flow cytometry.
Genetic vaccines and vaccine components can also be tested for their ability to induce humoral immune responses, as evidenced, for example, by the induction of production of B-cell antibodies specific for an antigen of interest. These assays can be conducted using, for example, peripheral B lymphocytes from immunized individuals. Such test methods are known to those skilled in the art. Other assays involve the detection of antigen expression by the target cells. For example, selection by FACS provides the most efficient method for identifying cells that produce a desired antigen on the cell surface. Another advantage of the selection by FACS is that different levels of expression can be followed; sometimes the lowest expression may be desired. Another method involves separation using monoclonal antibodies on a plate. This method allows a large number of cells to be handled in a short time, but the method only selects the levels with the highest expression. The capture by magnetic fabrics coated with monoclonal antibodies provide another method to identify the cells that express a particular antigen. Genetic vaccines and components of the vaccine that are directed against cancer cells can be selected for their ability to inhibit the proliferation of tumor cell lines in vi tro. Such assays are known in the art. An indication of the effectiveness of a genetic vaccine against, for example, a cancerous or autoimmune disorder, is the degree of inflammation of the skin when the vector is injected into the skin of a patient or test animal. The strong inflammation correlates with a strong activation of antigen-specific T cells. Improved activation of tumor-specific T cells can lead to better tumor elimination. In the case of antioantigens, immunomodulators can be added that shift the responses towards TH2. Skin biopsies can be taken, allowing detailed studies of the type of immune response that occurs at the sites of each injection (a large number of injections / vectors can be analyzed in mice). Other suitable separation methods can detect the expression of changes in the expression of cytokines, chemokines, accessory molecules, and the like, by cells after challenge by a library by gene vaccine vectors.
3. Improved Entry of Vectors of Genetic Vaccines in Cells The method involves subjecting the polynucleotides that dormant the DNA that are involved in the entry to the cell. Such polynucleotides are referred to herein as "transfer sequences" or "transfer module". Transfer modules can be obtained that increase the transfer in a specific, cellular way or that act in a more general way. Because the exact sequences that affect the binding and transfer of DNA are not known, often the lethargy or dragging of DNA may be the only efficient method to improve the ability of DNA to enter the cytoplasm and subsequently the nucleus of cells human The methods involve recombining at least the first and second forms of a nucleic acid comprising a transfer sequence. The first and second forms differ among themselves in two or more nucleotides. Suitable substrates include, for example, transcription factor binding sites, CpG sequences, polynucleotides A, C, G, T, and random DNA fragments such as, for example, genomic DNA, human or other animal species. It has been suggested that cell surface proteins such as the 'macrophage scavenging receptor, can act as receptors for specific DNA binding (Pisetsky (1996) Immunity 5: 303). It is not known if these receptors recognize specific DNA sequences or if they bind to DNA in a sequence in a non-specific way. However, GGGG tetrads have been shown to increase DNA binding to cell surfaces (Id.). In addition to the DNA sequence, the three-dimensional structure of the plasmids may play a role in the ability of these plasmids to enter the cells. The methods of lethargy or entrainment of the DNA of the invention provide means to optimize such sequences by their ability to confer a vector the ability to enter a cell even in the absence of detailed information on the mechanism by which this effect is achieved. The library resulting from the recombinant transfer modules are separated to identify at least one optimized recombinant transfer module that increases the capacity of a vector comprising the transfer module to enter a cell of interest. For example, vectors that include a recombinant transfer module can be contacted with a population of cells under conductive conditions for entry of the vector into the cells, after which the percentage of cells 1?
in the population that contains the nucleic acid vector. Preferably, the vector will contain a selectable or separable marker to facilitate identification of cells that contain the vector. In a preferred embodiment, the clonal isolates of the vectors containing the recombinant segments are used to infect separate cell cultures. The percentage of vectors that enter the cells can then be determined, for example, by counting the cells expressing a marker expressed by the vectors in the course of transfection. Typically, the recombinant process is repeated by recombining at least one optimized transfer sequence with an additional form of the transfer sequence to produce an additional library of recombinant transfer modules. The additional form may be the same or different from the first and second forms. The new library is separated to identify at least one additional optimized recombinant vector module that exhibits an improvement in the capacity of a genetic vaccine vector that includes the transfer module optimized to enter a cell of interest. The recombination and reseparation process can be repeated if necessary, until a transfer module having a sufficient capacity to improve the transfer is obtained. After one or more of the recombinations and separation, vector modules are obtained which are capable of conferring to a nucleic acid vector the ability to enter at least more than 50% of the target cells than a control vector not containing the optimized module, more preferably at least about more than 75 percent, and more preferably at least approximately more than 95 or 99 percent of the target cells that a control vector. Although for vaccine purposes, non-integral vectors are generally preferred, for some applications it may be desirable to use an integrating vector; for those applications the DNA sequences that directly or indirectly affect the integration efficiency can be included on the vector of the genetic vaccine. For integration by homologous recombination the important factors are the degree and length of the homology with the chromosomal sequences, as well as the frequency of such sequences in the genome (for example, Alu repeats). The homologous recombination that mediates the specific sequence is also important, since integration occurs more easily in the transcripcisnally active DNA. Methods and materials for constructing objective homologous constructs are described, for example, by Mansour (1988) Nature 336: 348; Bradley (1992) Bio / Technology 10: 534. For non-homologs, illegitimate and site-specific recombination is mediated by specific sites on the vector for therapy that interacts with the encoded recombinant proteins, for example, the Cre / Lox and Flp / Frt systems. See, for example, Baubonis (1993) Nucleic Acids Res. 21: 2025-2029, who report that a vector that includes a LoxP site is integrated into a LoxP site at the chromosomal site in the presence of a Cre recombinase enzyme.
C. Evolution of Union Polypeptides that Improve the Specificity and Efficiency of Genetic Vaccines The present invention also provides methods for obtaining recombinant nucleic acids encoding polypeptides which enhance the ability of genetic vaccines to enter target cells. Although the mechanisms involved in the absorption of DNA are not well understood, the methods of the invention allow to obtain genetic vaccines that exhibit better entry to cells, and to appropriate cellular compartments. In one embodiment, the invention provides methods for improving the efficiency and specificity of the uptake of a genetic vaccine nucleic acid by a given cell type by coating the nucleic acid with an evolved protein that binds to the nucleic acid of the genetic vaccine, also is able to join the target cell. The vector can be contacted with the protein in vi tro or in vivo. In the latter situation, the protein is expressed in cells that contain the vector, optionally of a coding sequence within the vector. The evolving nucleic acid binding proteins usually have nucleic acid binding activity but do not necessarily have any known ability to improve or alter the absorption of nucleic acid DNA. DNA binding proteins that can be used in those methods, include but are not limited to, transcriptional regulators, enzymes involved in the reproduction of DNA (eg, recA) and recombination of DNA, and proteins that serve for structural functions on DNA (for example, histones, protamines). Other DNA binding proteins that can be used include the repressor of phage 434, the repressor of phage lambda cl and ero, the Cap E. coli protein, myc, proteins with zippers of leucine and basic domains of DNA binding such as fos and jun; proteins with "POU" domains such as the paired Drosophila protein; proteins with domains whose structures depend on chelation with a metal ion such as zinc Cys2His2 found in TFIIIA, Zn2 (Cys) 6 clusters such as those in yeast Gal'4, the Cys His box found in retroviral nucleocapsule proteins , and the Zn2 (Cys) s clusters found in proteins of the nuclear hormone receptor type; p22 phage repressors Are and Mnt (see Knight et al (1989) J. Biol. Chem. 264: 3639-3642 and Bowie &Saur (1989) J. Biol. Chem 264: 7596-7602. RNA are reviewed by Burd &Dreyfuss (1994) Science 265: 615-621, and include the Tat and Rev of HIV.As other methods of the invention, the evolution of DNA binding proteins towards the acquisition of an efficiency Enhanced or altered absorption is effective in one or more cycles of recombination and separation Initial substances may be segments of nucleic acid encoding natural or induced variants of one or more nucleic acid binding proteins such as those mentioned above. The nucleic acid segments may be present in the vector or in isolates for the recombination step, recombination may proceed through any of the formats described herein.
8
For separation purposes, the recombinant nucleic acid segments are typically inserted into a vector, if they are not already present in such a vector during the recombination step. The vector generally codes for a selective marker that is capable of being expressed in the type of cell for which absorption is desired. If the evolving DNA binding protein recognizes a specific binding site (for example, the lacl binding protein recognizes lacO), this binding site can be included in the vector. Optionally, the vector can contain multiple cascade binding sites. Vectors containing different recombinant segments are transformed into a host cell, usually E. coli to allow the recombinant proteins to be expressed and bind to the vector coding for their genetic material. Most cells absorb only a single vector and thus the transformation results in a population of cells, most of which contain a single vector species. After an appropriate period to allow expression and binding, the cells are used under moderate conditions that do not disturb the binding of the vector to the DNA binding proteins. For example, a lysis buffer of HEPES 35 Mm (pH 7.5 with KOH). 0.1 mM EDTA, 100 mM Ma glutamate, 5% glycerol, 0.3 mg / ml BSA, 1 mM DTT, and 0.1 mM PMSF) plus lysozyme (0.3 ml to 10 mg / ml) is adequate (see Schatz et al. , Us 5,338,665). The vector binding protein and nucleic acid complexes are then contacted with cells of the type for which enhanced or altered absorption is desired under conditions that promote absorption. Suitable cells include the types of human cells that are common targets in DNA vaccination. Those cells include muscle cells, monocytes / macrophages, dendritic cells, B cells, Langerhans cells, keratinocytes, and M cells of the intestine. Mammalian cells including, for example, humans, mice and monkeys can be used for separation. The primary cells and the cells obtained from cell lines are suitable. After incubation, the cells are cultured with the selection for the expression of the selective marker present in the vector containing the recombinant segments. The cells expressing the marker are recovered. These cells are enriched in the recombinant segments that code for the nucleic acid binding proteins that increase the absorption of the vectors encoding the respective recombinant segments. The recombinant segments of the cells expressing the marker can then be subjected to an additional round of selection. Usually, the recombinant segments are first recovered from the cells, for example, by PCR amplification or by recovery of all vectors. The recombinant segments can then be recombined with one another or with other sources of DNA binding protein variants to generate additional recombinant segments. The additional recombinant segments are selected in the same manner as above. An example of a method for evolving an optimized nucleic acid protein involves the lethargy or entrainment of the histone genes. The DNA condensed with Histone may result in an increase in the transfer of the gene to the cells. See, for example, Fritz et al. (1996) Human Gene Therapy 7: 1395-1404. In this way, the lethargy or drag of the DNA can be used to evolve the histone protein, particularly the carboxy and amino-terminal peptide extensions, to increase the efficiency of DNA transfer to the cells. In this method, histone is encoded by the DNA to which it will bind. The histone library can be constructed, for example, 1) by lethargy or by dragging many of the related histone genes of a natural diversity, 2) the addition of random or partially random peptide sequences in the N- and C-terminal sequences of histone, 3) by the addition of preselected N-or C-terminal protein coding regions, such as complete cDNA libraries, nuclear protein ligand libraries, etc. These proteins can be randomized and partially linked to histone by a library of binders. In a variation of the above process, a binding site recognized by a nucleic acid binding protein can be evolved in place of, or as well as, the nucleic acid binding protein. The nucleic acid binding sites are evolved by means of a procedure analogous to nucleic acid binding proteins except that the initial substrates contain variable binding sites and the recombinant forms of those sites are separated as a component of the vector which also codes for a nucleic acid binding protein. The segments of nucleic acid that evolved, which code for the DNA binding proteins and / or the DNA binding sites that evolved can be included in gene vaccine vectors. If the affinity of the DNA binding protein is specific to a known DNA binding site, it is sufficient to include that binding site and the sequence encoding the DNA binding protein in the genetic vaccine vector together with such other coding and regulatory sequences as required to effect genetic therapy. In some cases, the DNA binding protein that evolved may not have a high degree of sequence specificity and may be unaware precisely which sites on the vector used in the separation are bound by the protein. In these circumstances, the vector should include all or most of the sequences of the separation vector together with the additional sequences required to effect the vaccination or therapy. The exemplary selection scheme employing the M13 VIII protein is shown in Figure 1. Target cells of interest include, for example, muscle cells, monocytes, dendritic cells, B cells, Langerhans cells, keratinocytes, M cells of the intestine, and similar. Cell-specific ligands that are suitable for use with each of the cell types are known to those skilled in the art. For example, proteins suitable for directing binding to antigen-presenting cells include the ligands CD2, CD28, CTLA-4, CD40 fibrinogen, factor X, ICAM-1, β-glycan (zymosan), and the Fc portion of the immunoglobulin G. (Weir's Handbook of Experimental Immunology, Eds. LA Herzenberg, DM Weir, LA Herzenberg, C. Blackwell, 5th edition, volume IV, chapters 156 and 174) because their respective ligands are present on APCs, including cells dendritic cells, monocytes / macrophages, B cells and Langerhans cells. The enterotoxins or bacterial subunits thereof are also of interest for management purposes. The ability of vectors to enter and activate APC, such as monocytes, can also be improved by coating the vectors in small amounts of lipopolysaccharide (LPS). This facilitates the interaction between the vector and the monocytes, which have a receptor on the cell surface for LPS. Due to its immunostimulatory activities, LPS probably also acts as an adjuvant, thus further enhancing immune responses. Enterotoxins produced by certain pathogenic bacteria are useful as agents that bind to cells and thus increase the release of vaccines, antigens, vectors for gene therapy and pharmaceutical proteins. In an exemplary embodiment of the invention, the receptor binding components of the enterotoxins' derived from Vibrio cholerae and enterotoxigenic strains of E. coli evolved to better binding to cell surface receptors and better entry to and transport through the cells. cells of the intestinal epithelium. In addition, they can evolve to a better binding to, and activation of, B cells different from APCs. An antigen of interest can be fused to these toxin subunits to illustrate the feasibility of the method in the oral delivery of proteins and to facilitate the separation of the subunits of enterotoxin that evolved. Examples of such antigens include growth hormone, insulin, myelin basic protein, collagen and viral envelope proteins. These methods involve recombining at least a first and second forms of a nucleic acid comprising a polynucleotide that encodes a non-toxic receptor binding portion, preferably an enterotoxin. The first and second forms differ from each other in two or more nucleotides, so that lethargy or DNA entrainment results in the production of a nucleic acid library from the binding portion of the recombinant enterotoxin. Suitable enterotoxins include, for example, an enterotoxin of V. cholerae, enterotoxins of enterotoxic strains of E. coli, Salmonella toxin, Shigella toxin and Campylobacter toxin. The vectors containing the nucleic acid library of the binding portion of recombinant enterotoxins are transfected into a population of host cells, where the nucleic acids of the binding portion of the recombinant enterotoxin are expressed to form the polypeptides of the binding portion. of the recombinant enterotoxin. In a preferred embodiment, the polypeptides of the binding portion of the recombinant enterotoxin are expressed as fusion enterotoxins on the surface of bacteriophage particles. The polypeptides of the binding portion of the recombinant enterotoxin can be separated by contacting the library with a receptor on the cell surface of a target cell and determining which polypeptides of the binding portion of the recombinant enterotoxin exhibit a greater capacity to bind to the receptor. of the target cell. The cell surface receptor may be present on the surface of a target cell itself, or it may be bound to a different cell, or the binding may be tested using a cell surface receptor that is not associated with a cell. Examples of suitable cell surface receptors include, for example, GM? - Similarly, super bacterial antigens can be evolved to alter (increase or decrease) receptor binding of T cells and MHC class II molecules. These super antigens activate the T cells in a non-specific form of the antigen. Antigens that bind to the T cell receptor / MHC class II molecules include enterotoxin B. Staphylococcal, the superantigen of Urtica dioica (Musette et al. (1996) Eur. J. Immunol. 26: 618-22) and enterotoxin A Staphylococcal (Bavari et al. (1996) J.
Infect. Dis. 174: 338-45). Phage display has been shown to be effective when selecting super antigens that bind MHC class II molecules
(Wung and Gascoigne (1997) J. Immunol. Methods 204: 3-41). Cholera toxin (CT) is a protein
• oligomeric of 84,000 daltons consisting of a toxic A subunit (CT-A) covalently linked to five B subunits (CT-B). CT-B functions as the receptor binding component and binds GMI ganglioside receptors on the surfaces of mammalian cells. The toxic A subunit does not necessarily serve CT function, and in the absence of CT-A, functional CT-B pentamers can be formed (Lebens and Holmgren (1994) Dev. Biol. Stand, 82: 215-227). Both CT and CT-B have been shown to have potent adjuvant activities in vivo and increase immune responses after oral administration of antigens and vaccines (Czerkinsky et al (1996) Ann. NY Acad. Sci. 778: 185 -93; Van Cott et al. (1996) Vaccine 14: 392-8). In addition, a single dose of CT and CT-B conjugated with myelin basic protein prevents the outbreak of autoimmune encephalomyelitis (EAE) is a murine model of multiple sclerosis (Czerkinsky et al., Supra.). In addition, the feeding of animals with myelin basic protein conjugated with CT-B after the onset of clinical symptoms (7 days) attenuated the symptoms in those animals. Other bacterial toxins, such as E. coli enterotoxins, Salmonella toxin, Shigella toxin and Campylobacter toxin, have structural similarities to CTs. E. coli enterotoxins have the same A-B structure as CTs since they also have sequence homology and share functional similarities. Bacterial enterotoxins can be evolved for improved affinity and entry to cells by lethargy or genetic entrainment. The similarity of the subunit of enterotoxin derived from E. coli and CT-B is 78%, and several completely conserved regions of more than eight nucleotides can be found. Subunits B of two different strains of E. coli are 98% homologous in both sequence and protein levels. In this way, it is feasible to carry the family DNA between the nucleic acids that code for the enterotoxin of different bacterial species. The libraries of the entrained toxin subunits can be expressed in a suitable host cell, such as V. cholerae. For safety reasons, strains in which toxic CT-A was suppressed are preferred. An antigen of interest can be fused to the receptor binding subunit. The secretion of chimeric proteins by V. cholerae can be selected by culturing the bacteria on agar in the presence of monoclonal antibodies specific for the antigen that was fused to the toxins and the level of secretion detected as immunoprecipitation in the agar around the colonies. Can GM ganglioside receptors also be added? to detect colonies that secrete functional enterotoxin subunits. Colonies that produce significant levels of the fusion protein are then cultured in 96-well plates, and the culture medium is tested for the presence of molecules capable of binding to cells or receptors in solution. The binding of chimeric fusion proteins to GM ganglioside receptors? on the cell surface or in solution can be detected by a monoclonal antibody specific for the antigen that was fused to the toxin. The assay using whole cells has the advantage that they can evolve to an improved binding also to receptors other than the GMi ganglioside receptor. When increasing concentrations of natural enterotoxins are added to these assays, mutants that bind to the receptors with better affinities can be detected. The affinity and specificity of the toxin binding can also be determined by surface plasmon resonance (Kuziemko et al (1996) Biochemistry 35: 6375-84). The advantage of the bacterial expression system is that the fusion protein is secreted by bacteria that could potentially be used in a large-scale production. further, because the fusion protein is in solution during selection, potential problems associated with phage display (such as the deviation towards mutant deviation that only works on the phage) can be avoided. However, phage display is useful for separation to identify enterotoxins with improved affinities. A library of carrion mutants can be expressed in phage, such as M13, and mutants with improved affinity are selected based on binding to, for example, ganglioside GMi receptors in solution or on a cell surface. The advantage of this method is that the mutants can be easily selected additionally in vivo assays as discussed below. A separation method using fusion to the M13 VIII protein is shown schematically in Figure 1. Finally, the resulting evolved enterotoxin can be fused with a DNA binding protein, and the genetic vaccine vectors coated with this protein fusion. The carrying of the DNA can be carried out separately, in which case the two domains are assembled after hauling, or in a combined reaction. Carrying results in the production of a nucleic acid library of the recombinant binding portion which can be selected by transfecting vectors which contain the library, as well as a specific binding site for the nucleic acid binding domain, in a population of host cells. The binding portion expressed in the cells and binds to the binding domain of the nucleic acid to 'form a complex vector-binding portion. The host cells can then be used under conditions that do not disturb the binding of the complex-binding portion. The vector-binding complex can then be contacted with a cell of interest, after which cells containing a vector are identified and the nucleic acids of the recombinant binding portion used are isolated from the cells. Another method for obtaining greater absorption of a target DNA with mammalian cells is also provided by the invention. Specifically, the method increases the number of copies of the target DNA absorbed in those cells that initially absorb the same DNA. The method uses cell surface expression of DNA-binding domains associated with the membrane of, for example, transcription factors, which are encoded in the DNA sequence
"Objective, which also includes the recognition sequence of cognates for the binding domain. The
Absorption of a target DNA molecule in a cell
(by any process, passive absorption, electroporation, osmotic shock, other stresses) will drive the transcription of the gene encoding the polynucleotide binding domain. The gene encoding the binding domain is designed so that the binding domain is expressed in an anchored form to the membrane. For example, a hydrophobic amino acid fragment can be encoded at the carboxyl terminus of the binding domain, thereby leading to phosphoinositol-glycan (PIG) conjugation after partial incision of this terminal sequence. This, in turn, leads to the displacement and positioning of the binding domain on the cell surface. The same cells that absorbed the first DNA molecule will express the factor and have a greater specific affinity for the target DNA that remains extracellular. Cells that do not absorb DNA will be at a competitive disadvantage, since they do not contain the specific binding domain of the cell surface target DNA, which is required for the absorption of specifically mediated DNA. The greater binding of the target DNA to the target cell will increase the internalization efficiency of the DNA and the desired intracellular function. This process represents a positive feedback to increase the absorption of DNA towards the cells that absorbed DNA for the first time. The target DNA, wherein a circular or linear plasmid, oligonucleotide, bacterial or mammalian chromosomal fragment, is designed to contain one or more copies of a DNA recognition sequence for a factor of. transcription of mammal or bacteria. Many objective sequences will already contain one or more such motifs; those can be identified by sequence analysis. The endogenous motifs recognized by these factors can also be experimentally identified by demonstrating that the target DNA binds to one or more panels of transcription factors in an appropriate assay format. This provides practical means to determine which factor or combination of factors to use with any particular target DNA. In the case of a small oligonucleotide or a DNA plasmid (such as that used for the DNA vaccine), suitable motifs can be designed in the sequence. A particular pattern can be designed in one or more copies, cascaded or an objective sequence dispersed. Alternatively, a set of different, cascaded or separate motifs may be designed in case where more than one DNA binding protein will be expressed on the cell surface.
D. Evolution of Bacteriophage Vectors The invention provides methods for obtaining bacteriophage vectors that exhibit desirable properties for use as vectors of genetic vaccines. The principle behind the method provided by the invention is to combine the power of DNA carryover with the extraordinary power of bacteriophage genetics and the knowledge of recent advances in phage display technologies to rapidly evolve vehicles for highly genetic vaccines. innovative and powerful. Evolved vaccine vehicles can present antigens (1) natively on the surface of the APCs for the induction of an antibody response or (2) selectively invade the APCs and release DNA vaccine constructs at the APCs for intracellular expression, processing and presentation to the CTL. The most efficient methods to release pathogen antigens to professional APCs will increase the kinetics and potency of the immune response to the vaccine. Delivery vehicles or distribution of genetic vaccines that have evolved according to the methods of the invention are particularly valuable for the rapid induction of high affinity antibodies which can effectively neutralize viral epitopes or pathogenic toxins., such as superantigens or cholera toxin. High affinity antibodies are generated by somatic mutation of low affinity primary response antibodies. This so-called affinity maturation process is essential for the generation of antibodies with sufficient affinity to neutralize the pathogenic antigens. Affinity maturation occurs in the spleen at the germinal center where follicular dendritic cells (FDC), the professional antigen presenting cells, present protein antigens to B cells and processed antigen fragments to T cells. Clonally expanding cell populations B, those that have undergone somatic mutation of those mutant B cells that express antibodies with improved affinity for the antigen are selected. Thus, efficient release of the antigen to CDF will increase the kinetics and potency of the immune response to the immunizing antigen. Additionally, the processed antigen bound to the MHC is required to stimulate the antigen-specific T cells. Genetic vaccines are particularly efficient in priming the restricted MHC class I responses due to the intracellular expression of the antigen, with resultant trafficking of antigen fragments towards the MHC class I pathway. Thus, Invasive bacteriophage vectors capable of releasing genetic vaccine constructs or protein antigens to FDCs are useful. Any of several bacteriophages can evolve according to the methods of the invention. The preferred bacteriophages for these purposes are those that have been well characterized and genetically developed to present external protein epitopes; those include, for example, bacteriophage lambda, T7 and M13. Filamentous phage M13 is a particular preferred vector for use in the methods of the invention. M13 is a small filamentous bacteriophage that has been widely used to present polypeptide fragments in folded, functional form on the surface of bacteriophage particles. The polypeptides have been fused to both coat proteins of gene I and gene VIII for such presentation purposes. In this way, the M13 is a highly evolved, versatile vehicle for the efficient and targeted release of protein or DNA vaccine vehicles to target cells of interest. The following three properties are examples of the type of environments that can be achieved by using the methods of the invention to evolve bacteriophage gene vaccine vectors: (1) efficient delivery of the phage to the bloodstream by inhalation or oral administration, (2) efficient search for APCs; and (3) efficient invasion of target cells using entrained bacterial invasion proteins. Where M13 is used, fusions can be made to both coat proteins of gene III and gene VIII, so that the properties that evolve can be combined into a single phage particle. These studies can be carried out in test animals such as laboratory mice so that the constructs that have evolved can be rapidly characterized with respect to their potency as vaccine carriers. The inhalable and / or orally releasable vehicles that have evolved and the invasins that have evolved will be directly transferred for use in human cells, although the principles developed in evolution as the ability to direct them to APC from test animals are easily transferable to human cells making analogous selections about human APCs. Although these methods are exemplified by bacteriophage vectors, the methods are also applicable to other types of gene vaccine vectors.
(1) Evolution of efficient release of bacteriophage vehicles by inhalation or oral delivery The invention provides methods for obtaining vectors of genetic vaccines that are capable of being released efficiently distributed to the bloodstream after administration by inhalation or by oral administration. The methods have been developed for the formulation of proteins in inhaled colloids that can be absorbed into the bloodstream through the lungs. The mechanisms by which proteins are transported into the bloodstream are not clearly understood, and thus improvements are easily exploited by evolutionary methods. Using M13 as an example, the invention involves the preparation of a library of, for example, peptide ligands, adhesion molecules, bacterial enterotoxins and randomly fragmented cDNA, which are fused to gene III, for example, of M13. Library of > 1010 individual mergers with this technology. The separation involves the preparation of patterns with a high titer (preferably> 1012 phage particles) in standard colloidal formulations, which are released or administered intranasally to test animals, such as mice. The blood samples are taken during the course of the next day and the circulating phages are amplified in E. coli. It has been established that M13 circulates for prolonged periods in the blood after being injected intravenously, and thus it is reasonable to expect that the phage that successfully enters the blood flow through the lung can be efficiently recovered and amplified in E. cells. coli In a preferred embodiment, several rounds of enrichment are applied to the initial libraries to enrich the phage that can efficiently enter the bloodstream when it is released intranasally. The candidate clones are typically individually tested to determine their relative input efficiency, and the best clones can be further characterized by sequencing to identify the nature of the fusion conferring efficient release (of particular interest to the cDNA libraries). ). The selected clones can be further evolved to improve entrainment of the whole phage genome and subjecting the phage to repeated cycles of release, recovery, amplification and entrainment. An analogous procedure was used to obtain vaccine vectors that are effective when released or orally administered. A genetic vaccine vector library was prepared by dragging the DNA. The recombinant vectors were packaged and administered to a test animal. Vectors that are stable in the stomach / intestinal environment were recovered, for example, by recovering the surviving vectors of the stomach. Vectors that efficiently enter the bloodstream and / or lymphatic tissue can be identified by recovering the vectors that reach the blood / lymph. An outline of this selection method is shown in Figure 2.
(2) Evolution of bacteriophage vehicles for efficient targeting of APCs The invention also provides methods for evolving bacteriophage vectors, as well as other types of gene vaccine vectors, for efficient targeting of professional antigen presenting cells. The libraries of random peptide ligands and cDNAs used in (A) above were enriched in phage, which binds selectively to APCs by first selecting negatively for binding to non-APC cell types, and then positively selecting for binding to the APC. The selection is typically carried out by mixing high-titer phage patterns of the libraries (> 1012 phage particles) with cells (~107 cells per selection cycle) and taking the unbound phage (negative selection) or the bound phage from the cellular sediments (positive selection). An alternative selection format consists of injecting phage libraries intravenously, allow the library to circulate for several hours, collect the target organs of interest (lymph nodes, spleen), and release the phage by sonication. The positively selected phage can be amplified in E. coli and additional rounds of enrichment are made (3-5 rounds) if further optimization is desired. After choosing the number of rounds, individual phages are characterized by their ability to target lymphoid organs. The best few Candidates can undergo further evolution through iterated rounds of selection, amplification and entrainment.
(3) Evolution of the bacteriophage for the invasion of APC The methods of the invention are also useful for evolving the bacteriophage and other vehicles of genetic vaccines for the invasion of target cells. This opens up the possibility of directing the MHC class I antigen processing pathways with internalized protein antigen or antigen expressed by cDNA vaccine vehicles carried by the evolved vector. The invasins comprise a large family of bacterial proteins, which interact with the integrins and promote the efficient internment of pathogenic bacteria such as Salmonella.
This embodiment of the invention involves displaying different forms of polynucleotides that encode for invasins. For example, two or more genes that code for the invasin family can be dragged. The entrained polynucleotides can be cloned as fusions to the coat protein gene of M13 gene VII, for example, high titer patterns of such libraries will be prepared. These bacteriophage libraries can be mixed with the target APC. After incubation, the cells are thoroughly washed to remove the free phage and the phage bound to the surfaces of the cells can be removed by separation in a tray against polyclonal anti-M13 antibodies. The cells are then sonicated, thereby releasing the phages that have successfully entered the target cells (thus protecting them from the anti-M13 polyclonal antiserum). These phages can, if desired, be amplified, dragged and the selective cycle will be applied interactively for example 3-5 times. The individual phage of the final cycle can then be characterized with respect to its relative invasiveness. The best candidates can then be combined with gene III fusions that code for the pathogenic epitopes of interest. That phage can be injected into mice and tested to determine their relative abilities to induce a CTL response to pathogenic antigens. Bacteriophage vaccine vehicles that evolved to have activity in mice according to the above methods will establish the principles for the evolution of similar vehicles for potent human vaccines. The ability to induce more rapid and potent CTL and neutralizing antibody responses with such vehicles is a new important tool for the evolution of improved countermeasures against the pathogens of interest.
Pharmaceutical Compositions of Genetic Vaccines and Administration Methods Release or delivery vehicles, vectors of engineered genetic vaccines, and components of the vector of the invention are useful for treating and / or preventing various diseases and other conditions. For example, genetic vaccines employing reagents obtained according to the methods of the invention are useful both in the prophylaxis and in the therapy of infectious diseases, including those caused by any bacteria, fungi, viruses or other pathogens of mammals. . The reagents obtained using the invention can also be used for the treatment of autoimmune diseases including, for example, rheumatoid arthritis, SLE, diabetes mellitus, myasthenia gravis, reactive arthritis, ankylosing spondylitis and multiple sclerosis. These and other inflammatory conditions, including IBD, psoriasis, pancreatitis, and various immunodeficiencies, can be treated using genetic vaccines that include vectors and other components obtained using the methods of the invention. Vectors of genetic vaccines and other vectors obtained using the methods of the invention can be used to treat allergies and asthma. In addition, the use of genetic vaccines is very promising for the treatment of cancer and the prevention of metastasis. By inducing an immune response against cancer cells, the body's immune system can be listed to reduce or eliminate cancer. In the preferred modalities so far, the reagents obtained using the invention are used in conjunction with a genetic vaccine. The choice of vector and components can also be optimized for the particular purpose of treating allergies or other conditions. For example, a ^ antigen for a particular condition can be optimized using methods of analogous recombination and selection those described herein. Such methods and antigens suitable for various conditions are described in U.S. Patent Application. Commonly assigned Serial No., entitled "Immunization of Antigenic Library," which was filed on February 10, 1999 as No. of Proxy File No. 18097-02871US. The polynucleotide encoding the recombinant antigenic polypeptide can be placed under the control of a promoter, for example, a high activity or specific tissue promoter. The promoter used to express the antigenic polypeptide can itself be optimized using methods of recombination and selection analogous to those described herein, as described in International Application No. PCT / US97 / 17300 (International Publication No. WO 98/13487). The vector may contain immunostimulatory sequences such as those described in U.S. Patent Application. copendiente, commonly assigned, Serial No., titled
"Optimization of Immunomodulatory Molecules", presented as Proxy File No. "TTC 18097-030300US" on February 10, 1999. Reagents obtained using the methods of the invention can also be used in conjunction with multi-component gene vaccines, which are capable of designing an immune response as is most appropriate to achieve a desired effect (see, for example, the co-pending US Patent Application, commonly referred to as No.
Series, entitled "Vaccine Vector Design
Genetics ", filed on February 10, 1999 as TFP File No. 18097-030100US) It is sometimes advantageous to employ a genetic vaccine that targets a particular type of target cell (e.g., an antigen-presenting cell or an antigen-presenting cell). an antigen processing cell), the appropriate methods of management are described in the commonly assigned co-pending US patent application Serial No., entitled "Vaccine Vectors Address
Genetics ", filed on February 10, 1999 as TTC File No. 18097-030200US.Genetic vaccines and delivery or delivery vehicles as described herein can be released to a mammal (including humans) to induce an immunotherapeutic response or The vaccine release vehicles can be released in vivo by administration to an individual patient, typically by systemic administration (eg, by the intravenous, intraperitoneal, intramuscular, subdermal, intracranial, anal, vaginal, oral, buccal routes or can inhaled) or can be delivered by topical application Alternatively, the vectors can be released into ex vivo cells, such as explanted cells from an individual patient (eg, lymphocytes, bone marrow aspirates, tissue biopsies) or hematopoietic germ cells from universal donors, followed by the reimplantation of the cells in a This is usually after the selection of the cells that have incorporated the vector. A large number of release methods are well known to those skilled in the art. Such methods include, for example, the release of genes based on liposomes (Debs and Zhu (1993) WO 93/24640;
Mannino and Gould-Fogerite (1988) BioTechniques 6 (7): 682-691; Rose Patent U.S. No. 5,279,833; Brigham (1991) WO
91/06309; and Felgner et al. (1987) Proc. Nati Acad. Sci. I USA 84: 7413-7414, as well as the use of viral vectors (eg, adenovirals (see, for example, Berns et al. (1995) Ann. NY Acad. Sci. 772: 95-104; Ali et al. al. (1994) Gene Ther.1: 367-384; and Haddada et al. (1995) Top Curr. Microbiol. Immunol. 199 (Pt 3): 297-306 for a review) papillomavirales, retrovirals (see, for example, "Buchscher et al. (1992) J. Virol. 66 (5) 2731- 2739; Johann et al. (1992) J. Virol. 66 (5): 1635-1640
(1992); Sommerfelt et al. , (1990) Virol. 176: 58-59;
Wilson et al. (1989) J. Virol. 63: 2374-2378; Miller et al., J. Virol. 65: 2220-2224 (1991); Wong-Staal et al. , PCT / US94 / 05700, and Rosenburg and Fauci (1993) in Fundamental Immunology, Paul Third Edition (ed) Raven Press, Ltd.,
New York and the references in it, and Yu et al., Gene
Therapy (1994) supra.), And adeno-associated viral vectors
(See West et al. (1987) Virology 160: 38-47; Carter et al. (1 * 989) US Patent No. 4,797,368; Carter et al., WO 93/24641 (1993); Kotin (1994) Human Gene Therapy 5: 793-801; Muzyczka (1994) J. Clin.Invest.94: 1351 and Samulski (supra) for an overview of AAV vectors, see also, Lebkowski, US Patent No. 5,173,414; Tratschin et al. 1985) Mol Cell Cell Biol. 5 (11): 3251-3260;
Tratschin et al. (1984) Mol. Cell. Biol., 4: 2072-2081; Hermonat and Muziczka (1984) Proc, Nati, Acad. Sci. USA, 81: 6466-6470; McLaughlin et al. (1988) and Samulski et al. (1989) J. Virol., 63: 03822-3828), and the like. The "naked" DNA and / or RNA comprising a genetic vaccine can be introduced directly into a tissue such as a muscle. See, for example, USPN 5,580,859. Other methods such as "biolistics" or particle-measured transformation (see, for example, # Sanford et al., USPN 4,945,050; USPN 5,036,006) are also suitable for the introduction of genetic vaccines into cells of a mammal according to the invention. These methods are useful not only for the in vivo introduction of DNA in a mammal, but also for the ex vivo modification of cells for reintroduction into a mammal. As for other methods of releasing genetic vaccines, if necessary, administration of the vaccine is repeated to maintain the desired level of immunomodulation. Genetic vaccine vectors (e.g., adenoviruses, liposomes, papillomaviruses, retroviruses, etc.) can be administered directly to the mammal for transduction of the cells in vivo. Genetic vaccines obtained using the methods of the invention can be formulated as pharmaceutical compositions for administration in any suitable manner, including palenteral (e.g., subcutaneous, intramuscular, intradermal or intravenous), topical, oral, rectal, intrathecal, buccal administration.
(for example, sublingual), or local administration, such as by aerosol or transdermally, for prophylactic and / or therapeutic treatment. Pretreatment of the skin, for example, by the use of hair or hair removal agents, can be useful in transdermal delivery. Suitable methods of administration of such packaged nucleic acids are available and are well known to those skilled in the art and, although more than one route can be used to administer a particular composition, a particular route often provides a more immediate and more effective reaction. what another route. The pharmaceutically acceptable carriers are determined in part by the particular composition being administered, as well as by the particular method of administering the composition. Accordingly, there is a wide variety of suitable formulations of pharmaceutical compositions of the present invention. A variety of aqueous carriers, eg, buffered saline and the like can be used.These solutions are sterile and are generally free of undesirable matter.These compositions can be sterilized by conventional, well-known sterilization techniques. pharmaceutically acceptable auxiliaries as required for approximate physiological conditions, such as pH adjusting agents and buffers, agents for adjusting toxicity and the like, eg, sodium acetate, sodium chloride, potassium chloride, calcium chloride Sodium lactate and the like The concentration of the genetic vaccine vector in those formulations can vary widely, and will be selected mainly on the basis of the volumes and viscosities of the fluids, body weight and the like according to the particular mode of administration selected. and the needs of the Formulations suitable for oral administration may consist of (a) liquid solutions, such as an effective amount of the packaged nucleic acid suspended in diluents, such as water, saline or PEG 400; (b) capsules, sacks or tablets, each containing a predetermined amount of the active ingredient, such as liquids, solids, granules or gelatin; (c) suspensions in an appropriate liquid; and (d) suitable emulsions. The tablet forms may include one or more of lactose, sucrose, mannitol, sorbitol, calcium phosphates, corn starch, potato starch, tragacanth, microcrystalline cellulose, acacia, gelatin, colloidal silicon dioxide, croscarmellose sodium, talc, stearate of magnesium, stearic acid and other excipients, colorants, fillers, binders, buffers, wetting agents, preservatives, flavoring agents, dyes, disintegrating agents and pharmaceutically compatible carriers. The tablet forms may comprise the active ingredient in a flavor, usually sucrose and acacia or tragacanth, as well as tablets comprising the active ingredient in an inert base, such as gelatin and glycerin emulsions or sucrose and acacia, gels and the like containing , in addition to the active ingredient, carriers known in the art. It is recognized that genetic vaccines when administered orally should be protected from digestion. This is typically achieved by complexing the vaccine vector with a composition to render it resistant to acidic and enzymatic hydrolysis or by packaging the vector in an appropriate resistant carrier, such as a liposome. Means for protecting digestion vectors are well known in the art. The pharmaceutical compositions can be encapsulated, for example, in liposomes or in a formulation that provides slow release of the active ingredient. Nucleic acids packaged alone or in combination with other suitable components can be made in aerosol formulations (for example, they can be "nebulized") to be administered via inhalation. Aerosol formulations can be placed in acceptable pressurized propellants, such as dichlorodifluoromethane, propane, nitrogen and the like. Formulations suitable for rectal administration include, for example, suppositories, which consist of the nucleic acid packaged with a suppository base. Suitable suppository bases include synthetic triglycerides or paraffinic hydrocarbons. In addition, it is also possible to use rectal gelatin capsules, which consist of a combination of the nucleic acid packaged with a base including, for example, liquid triglycerides, polyethylene glycols and paraffinic hydrocarbons. Formulations suitable for parenteral administration, such as, for example, intraarticular (in the joints), intravenous, intramuscular, intradermal, intraperitoneal and subcutaneous routes, include sterile, isotonic aqueous and non-aqueous injection solutions, which may contain antioxidants, buffers, bacteriostats and solutes to make the formulation isotonic with the intended recipient's blood, and sterile aqueous and non-aqueous suspensions which may include suspending agents, solubilizers, thickening agents, stabilizers and preservatives. In the practice of this invention, the compositions may be administered, for example, by intravenous, oral, topical, intraperitoneal, intravesicular or intrathecally infusion. Parenteral administration and intravenous administration are the preferred methods of administration. Packaged nucleic acid formulations can be presented in a sealed container with unit doses or multiple doses, such as ampoules and flasks. The injection solutions and suspensions can be prepared with sterile powders, granules, and tablets of the type described above. The cells transduced by the packaged nucleic acid can also be administered intravenously or parenterally. The dose administered to a patient, in the context of the present invention, should be sufficient to effect a beneficial therapeutic response to the patient over time. The dose will be determined by the efficacy of a particular vector employed and the condition of the patient, as well as the body weight or vascular surface area of the patient to be treated. The size of the dose will also be determined by the existence, nature and degree of any adverse side effects that accompany the administration of a particular vector, or a cell type transduced to a particular patient. The determination of the effective amount of the vector to be administered in the prophylaxis treatment of an infection or other condition, the physician assesses the toxicity of the vector, progress of the disease, and the production of anti-vector antibodies if any. In general, the equivalent dose of a naked nucleic acid from a vector is from about 1 μg to 1 mg for a typical 70 kilogram patient, and the doses of the vectors used to deliver the nucleic acid is calculated to produce an equivalent amount of therapeutic nucleic acid. The administration can be carried out via a single dose or divided dose. In therapeutic applications, the compositions are administered to a patient suffering from a disease (eg, an infectious disease or autoimmune disorder) in an amount sufficient to cure or at least partially counteract the disease and its complications. An adequate amount to achieve this is defined as "therapeutically effective dose". The effective amounts for this use will depend on the severity of the disease and the general state of the patient's health. Single or multiple administrations of the compositions can be made depending on the doses and efficacy required and tolerated by the patient. In any case, the composition should provide a sufficient amount of the proteins of this invention to effectively treat the patient. In prophylactic applications, the compositions they are administered to a human or other mammal to induce an immune response that can help protect against the establishment of an infectious disease or other condition. The toxicity and therapeutic efficacy of the genetic vaccine vectors provided by the invention are determined using standard therapeutic methods in cell cultures or experimental animals. The LD50 (lethal dose for 50% of the population) and ED50 (the therapeutically effective dose in 50% of the population) can be determined using the procedures presented herein or those in other circumstances known to those skilled in the art. A typical pharmaceutical composition for intravenous administration would be from about 0.1 to 10 mg per patient per day. Doses of 0.1 to approximately 100 mg per patient per day can be used, particularly when the drug is administered to a programmed site and not to the blood flow, such as in a body cavity or in the lumen of an organ. Substantially higher doses are possible in topical administration. The actual methods for preparing parenterally administrable compositions will be known or apparent to those skilled in the art and are described in greater detail in publications such as Remington's Pharmaceutical Science, 15th edition, Mack Publishing Company, Easton, Pennsylvania (1980). The multivalent antigenic polypeptides of the invention, and the genetic vaccines that express the polypeptides, can be packaged in packages, devices, distributors and equipment for administering genetic vaccines to a mammal. For example, distribution packages or devices that may contain one or more unit dosage forms are provided. Typically, instructions for the administration of the compounds will be provided by the package, along with an adequate indication on the label that the compound is suitable for the treatment of an indicated condition. For example, the label may establish that the active compound within the package is useful for treating a particular infectious disease, autoimmune disorder, tumor, or for preventing or treating other diseases or conditions that are mediated by, or are potentially susceptible to, a response immune of mammal. Example 1 Improvement of Bacterial Enterotoxin Properties by DNA Drag This Example describes the use of DNA entrainment methods to evolve the enterotoxin receptor binding components derived from Vibrio cholerae and E. coli enterotoxic strains for binding Improved cell surface receptors and for improved entry and transport through intestinal epithelial cells. An antigen of interest can be provided to those toxin subunits to facilitate the separation of the subtypes of enterotoxin that have evolved, and also to facilitate the oral release of proteins. Examples of such antigens include growth hormone, insulin, myelin basic protein, collagen and viral envelope proteins. Bacterial enterotoxins are evolved to an affinity and improved entry to cells by genetic entrainment. The similarity of the subunit of the enterotoxin derived from E. coli to the cholera toxin CT-B is 78%, and several fully conserved regions of eight nucleotides are present. An alignment of the DNAs encoding CT-B and the subunits of enterotoxin B from two strains of E. coli is shown in Figure 3 to illustrate the feasibility of family DNA tracing. In one embodiment, the libraries of the entrained toxin subunits are expressed in V. cholerae. For safety reasons, strains were used in which the toxic CT-A was removed. An antigen of interest was fused to the receptor binding subunit. The secretion of chimeric proteins by V. cholerae can be separated by culturing the bacteria on agar in the presence of monoclonal antibodies specific for the antigen that was fused to the toxins, and detecting the level of secretion as immunoprecipitation in the agar around the colonies. In addition, GMi ganglioside receptors can also be added to the agar to detect colonies that secrete functional enterotoxin subunits. Colonies that produce significant levels of the fusion protein are then cultured in 96-well plates, and the culture medium is tested for the presence of molecules capable of binding to cells or receptors in solution. The binding of chimeric fusion proteins to ganglioside GMi receptors on the cell surface or in solution can be detected by means of a monoclonal antibody specific for the antigen that was fused to the toxin. The assay using whole cells has the advantage that they can be evolved to improve binding also to other receptors than the GM ganglioside receptor? <; When increasing concentrations of natural enterotoxins are added to these assays, mutants that bind to receptors with improved affinities can be detected. Enterotoxins with improved affinities can also be separated using phage display methods. A library of carrion mutants can be expressed on phage, such as M13, and mutants with improved affinity are selected based on binding to the ganglioside GMi container in solution or on cell surfaces. The advantage of this method is that the mutants can be further selected easily in in vivo assays as discussed below. The separation of the improved oral release of vaccines and proteins can be carried out both in vi tro and in vivo. The in vitro method is based on Caco-2 cells (human colon adenocarcinoma) that are cultured in tissue culture. When grown on semipermeable filters, those cells spontaneously differentiate into cells that resemble epithelium of the human small intestine both structurally and functionally (Hilgers et al (1990) Pharm. Res. 7: 902-910). The harvested toxin recombinants, fused to an antigen of interest, are placed on top of this cell layer and the beneficial mutants are detected by measuring the level of antigen transport through the cell layer. Both mutants expressed in bacteria and phage can be selected using this method. Alternatively, and additionally, the mutants are separated in vivo. When expressed on a phage, the library of entrapped enterotoxin recombinants can be separated by their better entry to the intestinal epithelium and blood flow after oral delivery. This separation system also allows the selection of mutants with the most potent adjuvant activities. The advantage of using the phage is that a large amount of phage can be given and the successful mutants can be recovered and used in subsequent rounds of trawling and selection.
Example 2 Generation and Transfection of Human Dendritic Cells; Evaluation of the Vectors that were Optimized for Those Cells The dendritic cells are the most potent antigen presenting cells known to date. This example illustrates the feasibility of using dendritic cells to separate vectors of genetic vaccines with improved properties, including efficient transfection, expression of antigens, stability, ability to present antigens. Figure 4A demonstrates the phenotype of freshly isolated monocytes and after a culture period of seven days in the presence of IL4 (400 U / ml) and GM-CSF (100 ng / ml). Cultured cells were negative for CD14, although they expressed CDla, HLA-DR, CD40, CD80 and CD86, which is a characteristic phenotype of dendritic cells (Chapuis et al. (1997) Eur. J. Immunol., 27: 431 -441). The cultured dendritic cells were then transfected with a vector encoding GTP driven by a CMV promoter. As shown in Figure 4B, the efficiency of the transfection of those cells is very low. However, a small percentage (~ 1%) of the cells expressed low levels of GFP two days after transfection under the conditions shown in the figure. These data illustrate the need for improvements in the efficiency of transfection of human dendritic cells. Very little is known about the mechanism that regulates the efficiency of transfection and transgenetic expression in dendritic cells, or how it can be improved. Therefore, DNA dragging is an ideal method, because it does not depend on an a priori assumption of the mechanisms that limit the process. The cultured dendritic cells described in this example provide the ability to select vector libraries as described here elsewhere.
Example 3 Selection of Release Vehicles Derived from
Bacteriophages Which Have Greater Ability to Enter Target Cells This example describes a protocol for the use of phage display to select polypeptides that can enter dendritic cells, for example, by endocytosis mediated by the receptor. A library of recombinant polynucleotides obtained by recombination of a nucleic acid binding domain and a ligand for a dendritic cell receptor is expressed in a phage display format. The phage display library is incubated with dendritic cells for a period of time, after which the cells are washed (typically multiple washes are performed using highly concentrated saline to remove the remaining extracellular phage.) The cells are then cultured and sonicated to release the phages that have been internalized.The phages that are released are then amplified in E. coli, and the polynucleotide encoding the recombination binding portion used is obtained.If desired, the optimized polynucleotide is subjected to recombination additional to obtain additional optimization.
In a variation of this scheme, a phagemid encoding both the recombinant ligand and a selectable or separable marker (e.g., a gene encoding the green fluorescent protein operably linked to a CMV promoter) can be used. The cells that have absorbed the phage can then be identified by placing the culture under selective conditions, or by methods such as fluorescence-activated cell selection.
EXAMPLE 4 Animal Model for Separating Vectors from Genetic Vaccines This example provides a mouse model system that is useful for separating and testing vectors of genetic vaccines in human skin in vivo. Human skin pieces were xenotransplanted on the back of SCID mice. Pieces of human skin can be obtained from infants subjected to circumcision, from skin removal operations due to, for example, cosmetic reasons, or from patients who experienced amputation due to, for example, accidents. These pieces are then transplanted onto the backs of CB-17 scid / scid (SCID) mice as described by others (Deng et al. (1997) Na ture Biotechnology 15: 1388-1391; Khavari et al. (1997) Adv.
Clin. Res. 15: 27-35; Qhoate ^ and Khavari (1997) Human Gene Therapy 8: 895-901). The vector libraries are selected, for example, after topical application to the skin. However, in an analogous manner, depending on the optimal immunization route, evolved vectors may also be selected after i.m., i.v., oral, anal or vaginal release. The DNA released into the skin can be in the form of a patch, in the form of a cream, in the form of naked DNA or a mixture of DNA and agent to increase transfection (such as proteases, lipases or lipids / liposomes), and can Apply after mechanical abrasion, after removal of hair or hair, or simply by adding a drop of DNA or a mixture of DNA-lipid / liposome on the skin. Similar release methods are applied to small animals, such as mice or rats, large animals, such as cats, dogs, cows, horses or monkeys, as well as humans. Suitable proteases and lipases that increase release include, but are not limited to, individual components or mixtures of the following: a protease (such as Alcalase or Savinase) with or without alpha-amylase, a lipase (such as Lipolase) ( Sarlo et al (1997) J. Allergy, Clin Immunol., 100: 480-7).
The recovery of the optimal vectors can be effected from transfected cells, for example, by PCR, or by recovering whole vectors. Vectors can be selected based purely on their ability to enter cells or by selecting only cells expressing the antigen encoded by the vector in normal mice, monkeys or SCID mice transplanted with human skin. For example, GFP can be used as a marker gene, and after the release to detect the cells that were transfected by fluorescence microscopy or flow cytometry. Positive cells can be isolated, for example, by flow cytometry based on cell separation. This format allows the selection of vectors that optimally express antigens in and transfect human cells in vivo. Additionally, they can be separated into mice by selecting vectors that are capable of inducing effective immune responses after release into the skin. Vectors that induce more specific antibodies or CTL responses can be selected, or can be selected based on the induction of the protective immune response after challenge with the corresponding pathogen. It should be understood that the examples and embodiments described herein are for illustrative purposes only and that they will suggest various modifications or changes in light thereof to those skilled in the art and that are included within the spirit and point of view of this application and scope of application. the attached claims. All publications, patents and patent applications cited herein are therefore incorporated by reference for all purposes. It is noted that in relation to this date, the best method known to the applicant to carry out the aforementioned invention, is that which is clear from the present description of the invention.
Claims (50)
- CLAIMS Having described the invention as above, the content of the following claims is claimed as property: 1. A method for obtaining a cell-specific binding molecule useful for increasing the absorption or specificity of a genetic vaccine to a target cell, the method is characterized in that it comprises: creating a library of recombinant polynucleotides, recombining from a nucleic acid encoding a polypeptide comprising a nucleic acid binding domain and a nucleic acid encoding a polypeptide comprising a specific binding domain of a cell; and selecting the library to identify a recombinant polynucleotide that encodes a binding molecule that can bind to a nucleic acid and a specific receptor of a cell. 2. A method for obtaining a specific binding portion of a cell useful for increasing the absorption or specificity of a genetic vaccine by a target cell, the method is characterized in that it comprises: (1) recombining at least one first and second forms of a nucleic acid comprising a polynucleotide encoding a nucleic acid binding domain and at least the first and second forms of a nucleic acid comprising a ligand specific for a cell that specifically binds to a protein on the surface of a cell interest, wherein the first and second forms differ from each other in two or more nucleotides, to produce a library of the nucleic acids encoding the recombinant binding portion; (2) transfect a library of vectors to a population of host cells, each of which comprises: a) a specific binding site for the nucleic acid binding domain and 2) a member of the nucleic acid library that encode for the recombinant binding portion, wherein the recombinant binding portion is expressed and binds to the binding site to form a vector-binding portion complex; (3) using the host cells under conditions that do not disrupt the binding of the vector-binding portion complex; (4) contacting the vector-binding portion complex with a target cell of interest; and (5) identifying the target cells containing a vector and isolating the nucleic acids from the specific binding portion of a recombinant cell, optimized, from those target cells. The method according to claim 2, characterized in that the method further comprises: (6) recombining at least one nucleic acid encoding the optimized recombinant binding portion with a further form of the polynucleotide encoding a binding domain of nucleic acid and / or a further form of the polynucleotide encoding a cell-specific ligand, which are the same or different from the first and second forms, to produce an additional library of the nucleic acids encoding the recombinant binding; (7) transfecting in a population of host cells a library of vectors comprising: a) a binding site specific for the binding domain of the nucleic acid and 2) the nucleic acids encoding the binding portion, recombinants, where the recombinant binding portion is expressed and binds to the binding site to form a vector-binding portion complex; (8) using the host cells under conditions that do not disrupt the binding of the vector-binding portion complex; (9) contacting the vector-binding portion complex with a target cell of interest and identifying the target cells containing the vector; and (10) isolating the nucleic acids from the recombinant binding portion of the target cells containing the vector; and (11) repeating (6) through (10), as necessary, to obtain a specific, optimized cell binding portion useful for increasing the uptake or specificity of a genetic vaccine vector by a target cell. 4. The method according to claim 2, characterized in that the method further comprises identifying specific binding portions of a cell that result in greater efficiency in the transfection of the target cells. 5. The method according to claim 2, characterized in that the nucleic acid binding domain is a DNA binding domain derived from a protein selected from the group consisting of a transcriptional regulator, a polypeptide involved in the reproduction or recombination of the DNA, a repressor, a histone, a protamine, a CAP protein from E. coli, myc, a protein that has a leucine zipper, a protein that has a basic DNA binding domain, a protein that has a POU domain, a protein that has a zinc finger, and a protein that has a box of Cys3His. 6. The method according to claim 2, characterized in that the nucleic acid binding domain is an RNA binding domain derived from a protein selected from the group consisting of HIV tat and HIV rev. The method according to claim 2, characterized in that the target cell of interest is selected from the group consisting of muscle cells, monocytes, dendritic cells, B cells, Langerhans cells, keratinocytes and M cells. according to claim 7, characterized in that the cell of interest is a professional antigen presenting cell. The method according to claim 8, characterized in that the antigen presenting cell is a dendritic cell, a monocyte / macrophage, a B cell or a Langerhans cell. The method according to claim 8, characterized in that the specific ligand of the cell comprises a polypeptide selected from the group consisting of the ligands CD2, CD28, CTLA-4, CD40, fibrinogen, ICAM-1 Fc portion of the immunoglobulin G, and a bacterial enterotoxin, or a subunit thereof. 11. The method according to claim 2, characterized in that the target cell of interest is a human cell. The method according to claim 2, characterized in that the target cells containing the vector are identified by selecting the expression of a selectable label contained in the vector. The method according to claim 2, characterized in that the nucleic acid encoding the recombinant binding portion comprises a genetic vaccine vector. 14. A recombinant portion of cell-specific binding, characterized in that it is produced by expressing in a host cell a nucleic acid encoding the used recombinant binding portion obtained by the method according to claim 2. 15. A genetic vaccine, characterized in that it comprises a specific recombinant binding portion of a cell according to claim 14. 16. A genetic vaccine, characterized in that it comprises a nucleic acid encoding the optimized, recombinant binding potion obtained in accordance with claim 2. 17. A genetic vaccine, characterized in that it comprises: a) an optimized recombinant binding portion comprising a nucleic acid binding domain and a specific ligand of a cell, and b) a polynucleotide sequence comprising a binding site, wherein the domain nucleic acid binding is able to bind specifically to the union site. 18. A method for obtaining a specific binding portion of an optimized cell useful for increasing the absorption, efficacy, or specificity of a genetic vaccine for a target cell, the method is characterized in that it comprises: (1) recombining at least the first and second forms of a nucleic acid comprising a polynucleotide that encodes a non-toxic receptor binding portion of an enterotoxin, where the first and second forms differ from each other in two or more nucleotides, to produce a library of recombinant nucleic acids; (2) transfecting the vectors containing the nucleic acid library in a population of host cells, wherein the nucleic acids are expressed to form polypeptides of the specific binding portion of the recombinant cell; (3) contacting polypeptides of the specific binding portion of the recombinant cell with a receptor on the cell surface of a target cell; Y (4) determining which polypeptides of the specific binding portion of the recombinant cell exhibit a greater ability to bind to the target cell. 19. The method according to claim 18, characterized in that the cell surface receptor is present on the surface of a target cell. 20. The method according to claim 18, characterized in that the cell surface receptor is GM- ?. 21. The method according to claim 18, characterized in that the host cell is a V. cholerae cell which is unable to express CT-A. 22. A method for increasing the uptake of a genetic vaccine vector by a target cell, the method is characterized in that it comprises coating the vector of the genetic vaccine with a recombinant, optimized, specific cell binding portion, produced by the method according to claim 18. 23. The method according to claim 18, characterized in that the cell-specific binding portions, recombinants, are expressed as a fusion protein on the surface of a reproducible genetic package. 24. A method for obtaining a genetic vaccine component that confers a vector a greater capacity to enter the antigen-presenting cell, the method is characterized in that it comprises: creating a library of recombinant nucleic acids by recombining at least two forms of a polynucleotide; contacting a library of vectors, each of which comprises a member of the recombinant nucleic acid library, with a population of antigen-presenting or antigen-processing cells; and determine the percentage of cells in the population that contain the vector. The method according to claim 24, characterized in that the antigen-presenting or antigen-processing cells are selected from the group consisting of B cells, monocytes / macrophages, dendritic cells, Langerhans cells, keratinocytes, and muscle cells. 26. The method according to claim 25, characterized in that the cells are B cells, which are obtained from a B cell line. The method according to claim 24, characterized in that the separation or selection is conducted in live and the cells are monkey cells or mouse cells. 28. The method according to claim 24, characterized in that the method further comprises: culturing the cells for a predetermined time after contacting the cells with the vector library; washing the cells after the contact step to remove the vectors that did not enter an antigen-presenting cell; and isolate vectors from cells that contain a vector. 29. The method according to claim 24, characterized in that cells containing a vector are identified: transfecting individual members of the library or sets of members of the library in separate cultures of antigen cells; cocultivating the cultures of the antigen presenting cells with T lymphocytes obtained from the same individuals as the antigen-presenting cells; and identifying the cultures in which a T lymphocyte response was induced. The method according to claim 29, characterized in that the response of the T lymphocytes is selected from the group consisting of an increase in the proliferation of the lymphocytes. T, increased cytolytic activity mediated by T lymphocytes against a target cell, and an increase in cytosine production. 31. The method according to claim 24, characterized in that the vector is a reproducible genetic package and the recombinant nucleic acids are expressed as a fusion protein, which is presented on the surface of the reproducible genetic package. 32. The method according to claim 31, characterized in that the reproducible genetic package is a bacteriophage. 33. A method to obtain a component of a genetic vaccine that confers a vector an increased ability to enter cells or tissues when * administered to a mammal by means of a desired administration protocol, the method is characterized in that it comprises: creating a library of recombinant nucleic acids by recombining at least two forms of a polynucleotide; administering to a mammal "a library of vectors, each comprising a member of the library of recombinant nucleic acids, in the mammal; obtain target cells or tissues of the mammal; identify target cells or tissues that contain a vector; and recovering the vector of the identified target cells or tissues. 34. The method according to claim 33, characterized in that the target cells are lymphatic cells. 35. The method according to claim 33, characterized in that the administration is by oral ingestion, inhalation, injection, or topical application to the skin or mucous membrane. 36. The method according to claim 33, characterized in that the vector is a reproducible genetic package and the recombinant nucleic acids are expressed as a fusion protein, which is presented on the surface of the reproducible genetic package. 37. A method for evolving a vaccine delivery vehicle to obtain an optimized delivery vehicle having a greater capacity to enter a selected mammalian tissue following administration to a mammal, the method is characterized in that it comprises: (1) recombining members of a set of polynucleotides to produce a library of recombinant polynucleotides; (2) administering to a test animal a library of reproducible genetic packets, each comprising a member of the library of recombinant polynucleotides operably linked to a polynucleotide encoding a display polypeptide, wherein the recombinant polynucleotide and the polypeptide of presentation are expressed as a fusion protein, which is presented on the surface of the reproducible genetic package; and (3) recovering the reproducible genetic packets that are present in the selected tissue of the test animal at an appropriate time after administration, where the retrieved, reproducible genetic package has a greater ability to enter the selected mammalian tissue following administration of the mammal . 38. The method according to claim 37, characterized in that the method further comprises: (4) recombining a nucleic acid comprising at least one recombinant polynucleotide obtained from a reproducible genetic package recovered from the selected tissue with an additional set of polynucleotides for produce an additional library of recombinant polynucleotides; (5) administering to a test animal a library of reproducible genetic packets, each of which comprises a member of the additional library of recombinant polynucleotides operably linked to a polynucleotide encoding a display polypeptide, wherein the recombinant polynucleotide and the presentation polypeptide is expressed as a fusion protein, which is presented on the surface of the reproducible genetic package; (6) recover reproducible genetic packets that are present in the selected tissue of the test animal at an appropriate time after administration; and (7) repeating (4) to (6), as necessary to obtain an additional optimized recombinant release vehicle that exhibits enhanced ability to enter a selected mammalian tissue following administration to a mammal. 39. The method according to claim 37, characterized in that the reproducible genetic package is a bacteriophage. 40. The method according to claim 39, characterized in that the bacteriophage is M13. 41. The method according to claim 40, characterized in that the polynucleotide encoding a presentation polypeptide is selected from the group consisting of gene II and gene VIII. 42. The method according to claim 37, characterized in that the selected mammalian tissue is blood flow and the administration is by inhalation. 43. The method according to claim 37, characterized in that the intravenous administration and the selected mammalian tissue is selected from the group consisting of lymph nodes and spleen. 44. A method for evolving a vaccine delivery vehicle to obtain an optimized delivery vehicle having greater specificity for antigen presenting cells, the method is characterized in that it comprises: (1) recombining the members of a set of polynucleotides to produce a library of recombinant polynucleotides; (2) producing a library of reproducible genetic packets, each comprising a library member of recombinant polynucleotides operably linked to a polynucleotide encoding a display polypeptide, wherein the recombinant polynucleotide and the display polypeptide are expressed as a fusion protein which is presented on the surface of the reproducible genetic package; (3) contacting the library of recombinant reproducible genetic packets with a non-APC to remove reproducible genetic packets that display specific non-APC fusion polypeptides; and (4) contacting recombinant reproducible genetic packets that do not bind to non-APC with an APC and recover those that bind to the APC, where the retrievable reproducible genetic packets are able to specifically bind to the APCs. 45. The method according to claim 44, characterized in that the method further comprises the steps of: (5) recombining a nucleic acid, which comprises at least one recombinant polynucleotide obtained from a reproducible genetic package that is capable of binding specifically to APC with an additional set of polynucleotides to produce an additional library of recombinant polynucleotides; (6) producing an additional library of recombinant reproducible genetic packets, each comprising a member of the library of recombinant polynucleotides operably linked to a polynucleotide encoding a display polypeptide, wherein the recombinant polynucleotide and the presentation polypeptide are expresses as fusion proteins, which is presented on the surface of the reproducible genetic package; (7) contacting the additional library of recombinant reproducible genetic packages with a non-APC to remove those that exhibit non-APC-specific fusion polypeptides; and (8) contacting the recombinant reproducible genetic packets that did not bind to non-APC with an APC and recover the reproducible genetic packets that bind to the APC, where the retrievable reproducible genetic packets are capable of specifically binding to APC; and (9) repeating (5) to (8), as necessary, to obtain an additional optimized recombinant release vehicle that exhibits greater specificity for antigen-presenting cells. 46. A method for evolving a vaccine delivery vehicle to obtain an optimized vaccine delivery vehicle having a greater capacity to enter a target cell, the method is characterized in that it comprises: (1) recombining at least the first and second forms of a nucleic acid encoding an invasin polypeptide, wherein the first and second forms differ from each other in two or more nucleotides, to produce a library of recombinant invasin nucleic acids; (2) producing a recombinant bacteriophage library, each of which has on the surface of the bacteriophage a fusion polypeptide encoded by a chimeric gene comprising a recombinant invasin nucleic acid operably linked to a polynucleotide encoding a presentation polypeptide; (3) contacting the recombinant bacteriophage library with a population of target cells; (4) removing the unbound phage and the phage that is bound to the surface of the target cells; and (5) recovering the phages that are present within the target cells where the recovered phages are rich in phage that have a greater capacity to enter the target cells. 47. The method according to claim 46, characterized in that the method further comprises: (6) recombining a nucleic acid which comprises at least one bacteriophage recombinant invasin nucleic acid, which is recovered from a target cell with a additional set of polynucleotides to produce an additional library of recombinant invasin polynucleotides; (7) producing an additional library of recombinant bacteriophage, each of which displays on the surface of the bacteriophage a fusion polypeptide encoded by a chimeric gene comprising a recombinant invasin nucleic acid operably linked to a polynucleotide encoding a presentation; (8) contacting the recombinant bacteriophage library with a population of target cells; (9) removing the unbound phage and the phage that bound to the surface of the target cells; and (10) recovering the phages that are present within the target cells; and (11) repeating (6) to (10), as necessary, to obtain an additional optimized recombinant release vehicle which exhibits greater capacity to enter the target cells. 48. The method according to claim 47, characterized in that the method further comprises: (12) inserting into the optimized recombinant delivery vehicle a polynucleotide, which codes for an antigen of interest, where the antigen of interest is expressed as a fusion polypeptide, which comprises a second polypeptide of presentation; (13) administering the delivery vehicle to a test animal; and (14) determining whether the delivery vehicle is capable of inducing a CTL response in the test animal. 49. The method according to claim 47, characterized in that the method further comprises: (12) inserting into the optimized recombinant release car a polynucleotide, which codes for an antigen of interest, where the antigen of interest is expressed as a fusion polypeptide, which comprises a second polypeptide of presentation; (13) administering the delivery vehicle to a test animal; and (14) determining whether the delivery vehicle is capable of inducing neutralizing antibodies against a pathogen which comprises the antigen of interest. 50. The method according to claim 46, characterized in that the target cell is an APC.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2176998A | 1998-02-11 | 1998-02-11 | |
US7429498P | 1998-02-11 | 1998-02-11 | |
PCT/US1999/003023 WO1999041402A2 (en) | 1998-02-11 | 1999-02-10 | Targeting of genetic vaccine vectors |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA00007893A true MXPA00007893A (en) | 2002-10-23 |
Family
ID=26695070
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA00007889A MXPA00007889A (en) | 1998-02-11 | 1999-02-10 | Optimization of immunomodulatory properties of genetic vaccines. |
MXPA00007893A MXPA00007893A (en) | 1998-02-11 | 1999-02-10 | Targeting of genetic vaccine vectors. |
MXPA00007891A MXPA00007891A (en) | 1998-02-11 | 1999-02-10 | Genetic vaccine vector engineering. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA00007889A MXPA00007889A (en) | 1998-02-11 | 1999-02-10 | Optimization of immunomodulatory properties of genetic vaccines. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA00007891A MXPA00007891A (en) | 1998-02-11 | 1999-02-10 | Genetic vaccine vector engineering. |
Country Status (6)
Country | Link |
---|---|
EP (3) | EP1056842A2 (en) |
JP (3) | JP2002507392A (en) |
AU (3) | AU3291099A (en) |
CA (3) | CA2320626A1 (en) |
MX (3) | MXPA00007889A (en) |
WO (3) | WO1999041369A2 (en) |
Families Citing this family (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6537776B1 (en) | 1999-06-14 | 2003-03-25 | Diversa Corporation | Synthetic ligation reassembly in directed evolution |
US6326204B1 (en) | 1997-01-17 | 2001-12-04 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
CA2301575C (en) | 1997-05-20 | 2003-12-23 | Ottawa Civic Hospital Loeb Research Institute | Vectors and methods for immunization or therapeutic protocols |
WO1999021979A1 (en) | 1997-10-28 | 1999-05-06 | Maxygen, Inc. | Human papillomavirus vectors |
EP1690868A1 (en) | 1997-10-31 | 2006-08-16 | Maxygen, Inc. | Modification of virus tropism and host range by viral genome shuffling |
US6908757B1 (en) | 1998-03-26 | 2005-06-21 | The Procter & Gamble Company | Serine protease variants having amino acid deletions and substitutions |
CA2335269A1 (en) | 1998-06-17 | 1999-12-23 | Maxygen, Inc. | Method for producing polynucleotides with desired properties |
EP1104459A1 (en) | 1998-08-12 | 2001-06-06 | Maxygen, Inc. | Dna shuffling of monooxygenase genes for production of industrial chemicals |
EP1119616A2 (en) | 1998-10-07 | 2001-08-01 | Maxygen, Inc. | Dna shuffling to produce nucleic acids for mycotoxin detoxification |
US6913749B2 (en) | 1998-11-02 | 2005-07-05 | Resistentia Pharmaceuticals Ab | Immunogenic polypeptides for inducing anti-self IgE responses |
AU1619400A (en) | 1998-11-10 | 2000-05-29 | Maxygen, Inc. | Modified adp-glucose pyrophosphorylase for improvement and optimization of plantphenotypes |
US6376246B1 (en) | 1999-02-05 | 2002-04-23 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
US6436675B1 (en) | 1999-09-28 | 2002-08-20 | Maxygen, Inc. | Use of codon-varied oligonucleotide synthesis for synthetic shuffling |
DE60044223D1 (en) | 1999-01-19 | 2010-06-02 | Maxygen Inc | BY OLIGONUCLEOTIDE-MEDIATED NUCLEIC ACID RECOMBINATION |
EP1073710A4 (en) * | 1999-02-04 | 2007-12-19 | Verenium Corp | Non-stochastic generation of genetic vaccines and enzymes |
KR20010102069A (en) | 1999-02-11 | 2001-11-15 | 추후제출 | High throughput mass spectrometry |
US6531316B1 (en) | 1999-03-05 | 2003-03-11 | Maxyag, Inc. | Encryption of traits using split gene sequences and engineered genetic elements |
JP2003505070A (en) | 1999-07-22 | 2003-02-12 | ザ、プロクター、エンド、ギャンブル、カンパニー | Subtilisin protease variants with amino acid substitutions in defined epitope regions |
EP1196548A2 (en) | 1999-07-22 | 2002-04-17 | The Procter & Gamble Company | Protease conjugates having sterically protected clip sites |
US6946128B1 (en) | 1999-07-22 | 2005-09-20 | The Procter & Gamble Company | Protease conjugates having sterically protected epitope regions |
AU5928100A (en) | 1999-07-22 | 2001-02-13 | Procter & Gamble Company, The | Subtilisin protease variants having amino acid deletions and substitutions in defined epitope regions |
US6686515B1 (en) | 1999-11-23 | 2004-02-03 | Maxygen, Inc. | Homologous recombination in plants |
US7115712B1 (en) * | 1999-12-02 | 2006-10-03 | Maxygen, Inc. | Cytokine polypeptides |
WO2001059071A2 (en) | 2000-02-09 | 2001-08-16 | Genvec, Inc. | Methods of preparing and using a viral vector library |
AU5995701A (en) * | 2000-05-26 | 2001-12-03 | Univ Australian | Synthetic peptides and uses therefore |
AUPQ776100A0 (en) * | 2000-05-26 | 2000-06-15 | Australian National University, The | Synthetic molecules and uses therefor |
US7094875B2 (en) | 2000-06-23 | 2006-08-22 | Maxygen, Inc. | Co-stimulatory polypeptides |
US7074590B2 (en) | 2000-06-23 | 2006-07-11 | Maxygen, Inc. | Chimeric promoters |
EP1299115A2 (en) * | 2000-06-26 | 2003-04-09 | Maxygen, Inc. | Methods and compositions for developing spore display systems for medicinal and industrial applications |
US6858422B2 (en) | 2000-07-13 | 2005-02-22 | Codexis, Inc. | Lipase genes |
DE10060959A1 (en) * | 2000-12-06 | 2002-06-20 | Aventis Res & Tech Gmbh & Co | Processes for isolating and identifying effectors |
AU2002314712C1 (en) * | 2001-02-02 | 2008-10-02 | Novici Biotech Llc | A method of increasing complementarity in a heteroduplex polynucleotide |
WO2002094992A2 (en) | 2001-05-18 | 2002-11-28 | Rigel Pharmaceuticals, Incorporated | Directed evolution of protein in mammalian cells |
WO2003008436A2 (en) * | 2001-07-19 | 2003-01-30 | Icogen Corporation | Methods for the identification of peptidyl compounds interacting with extracellular target molecules |
CN101670119A (en) * | 2001-11-21 | 2010-03-17 | 利兰·斯坦福青年大学托管委员会 | polynucleotide |
WO2003102166A2 (en) | 2002-02-26 | 2003-12-11 | Maxygen, Inc. | Novel flavivirus antigens |
DK2315145T3 (en) | 2002-03-01 | 2016-01-25 | Codexis Mayflower Holdings Llc | Methods, systems, and software for identifying the functional biomolecules |
AU2003213846A1 (en) | 2002-03-09 | 2003-09-29 | Maxygen, Inc. | Optimization of crossover points for directed evolution |
US7226771B2 (en) | 2002-04-19 | 2007-06-05 | Diversa Corporation | Phospholipases, nucleic acids encoding them and methods for making and using them |
PT1497418E (en) | 2002-04-19 | 2013-01-25 | Dsm Ip Assets Bv | Phospholipases, nucleic acids encoding them and methods for making and using them |
US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
WO2005003289A2 (en) | 2002-08-06 | 2005-01-13 | Verdia, Inc. | Ap1 amine oxidase variants |
EP1575601B1 (en) | 2002-12-16 | 2015-07-01 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Recombinant vaccine viruses expressing il-15 and methods of using the same |
ES2713024T3 (en) | 2003-03-06 | 2019-05-17 | Basf Enzymes Llc | Amylases, nucleic acids that encode them and methods for their manufacture and use |
US8298799B2 (en) | 2003-03-07 | 2012-10-30 | Dsm Ip Assets B. V. | Hydrolases, nucleic acids encoding them and methods for making and using them |
ES2545639T3 (en) | 2003-04-04 | 2015-09-14 | Basf Enzymes Llc | Pectate liases, nucleic acids that encode them and methods for their preparation and use |
MXPA05011585A (en) | 2003-04-29 | 2006-05-25 | Pioneer Hi Bred Int | Novel glyphosate-n-acetyltransferase (gat) genes. |
NZ570709A (en) * | 2003-06-13 | 2010-04-30 | Univ Pennsylvania | Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same |
BRPI0412279A (en) | 2003-07-02 | 2006-09-19 | Diversa Corp | glucanases, nucleic acids encoding the same and methods for preparing and applying them |
WO2005021714A2 (en) | 2003-08-11 | 2005-03-10 | Diversa Corporation | Laccases, nucleic acids encoding them and methods for making and using them |
CA2734716A1 (en) | 2004-06-09 | 2005-12-29 | Pioneer Hi-Bred International, Inc. | Plastid transit peptides |
EP2468853B1 (en) | 2004-06-16 | 2015-04-01 | DSM IP Assets B.V. | Method for enzymatic decolorization of pheophytin |
GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
CA2614769A1 (en) | 2005-03-10 | 2006-09-21 | Verenium Corporation | Lyase enzymes, nucleic acids encoding them and methods for making and using them |
NZ594810A (en) | 2005-03-15 | 2012-12-21 | Verenium Corp | Cellulases, nucleic acids encoding them and methods for making and using them |
US8715988B2 (en) | 2005-03-28 | 2014-05-06 | California Institute Of Technology | Alkane oxidation by modified hydroxylases |
EP1987142A4 (en) | 2006-02-02 | 2009-07-15 | Verenium Corp | Esterases and related nucleic acids and methods |
NZ595499A (en) | 2006-02-10 | 2013-05-31 | Verenium Corp | Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them |
PL1989302T3 (en) | 2006-02-14 | 2019-03-29 | Bp Corp North America Inc | Xylanases, nucleic acids encoding them and methods for making and using them |
MX2008011477A (en) | 2006-03-07 | 2008-09-23 | Cargill Inc | Aldolases, nucleic acids encoding them and methods for making and using them. |
EA029538B1 (en) | 2006-03-07 | 2018-04-30 | Басф Энзаймс Ллк | Polypeptide having aldolase activity, polynucleotide encoding this polypeptide and methods for making and using the polynucleotide and polypeptide |
CN103397043A (en) | 2006-08-04 | 2013-11-20 | 维莱尼姆公司 | Glucanases, nucleic acids encoding same and method for making and using same |
PL2057274T3 (en) | 2006-09-21 | 2014-05-30 | Dsm Ip Assets Bv | Phospholipases, nucleic acids encoding them and methods for making and using them |
PT2617823E (en) | 2006-09-21 | 2015-11-23 | Basf Enzymes Llc | Phytases, nucleic acids encoding them and methods for making and using them |
EP2479267B1 (en) | 2006-12-21 | 2016-12-21 | BASF Enzymes LLC | Amylases and glucoamylases, nucleic acids encoding them and methods for making and using them |
CA2674721C (en) | 2007-01-30 | 2018-04-03 | Verenium Corporation | Enzymes for the treatment of lignocellulosics, nucleic acids encoding them and methods for making and using them |
CN110577945A (en) | 2007-10-03 | 2019-12-17 | 维莱尼姆公司 | xylanases, nucleic acids encoding them, and methods for making and using them |
EP2222697B1 (en) | 2007-11-01 | 2012-12-05 | Perseid Therapeutics LLC | Immunosuppressive polypeptides and nucleic acids |
EP2238261B1 (en) | 2008-01-03 | 2013-12-04 | Verenium Corporation | Isomerases, nucleic acids encoding them and methods for making and using them |
ES2531290T3 (en) | 2008-01-03 | 2015-03-12 | Basf Enzymes Llc | Transferases and oxidoreductases, nucleic acids that encode them and methods to prepare and use them |
EP2297310A2 (en) | 2008-05-23 | 2011-03-23 | E. I. du Pont de Nemours and Company | Novel dgat genes for increased seed storage lipid production and altered fatty acid profiles in oilseed plants |
US8198062B2 (en) | 2008-08-29 | 2012-06-12 | Dsm Ip Assets B.V. | Hydrolases, nucleic acids encoding them and methods for making and using them |
CN102227503B (en) | 2008-09-26 | 2015-10-21 | 托卡根公司 | Recombinant vectors |
VN30065A1 (en) | 2009-05-21 | 2012-06-25 | Verenium Corp | Phytases, nucleic acids encoding them and methods for making and using them |
IN2012DN01359A (en) | 2009-08-20 | 2015-06-05 | Pioneer Hi Bred Int | |
UA109884C2 (en) | 2009-10-16 | 2015-10-26 | A POLYPEPTIDE THAT HAS THE ACTIVITY OF THE PHOSPHATIDYLINOSYTOL-SPECIFIC PHOSPHOLIPASE C, NUCLEIC ACID, AND METHOD OF METHOD | |
UA111708C2 (en) | 2009-10-16 | 2016-06-10 | Бандж Ойлз, Інк. | METHOD OF OIL REFINING |
WO2011082304A1 (en) | 2009-12-31 | 2011-07-07 | Pioneer Hi-Bred International, Inc. | Engineering plant resistance to diseases caused by pathogens |
EP2603591A1 (en) | 2010-08-13 | 2013-06-19 | Pioneer Hi-Bred International Inc. | Compositions and methods comprising sequences having hydroxyphenylpyruvate dioxygenase (hppd) activity |
WO2013166113A1 (en) | 2012-05-04 | 2013-11-07 | E. I. Du Pont De Nemours And Company | Compositions and methods comprising sequences having meganuclease activity |
BR112015023286A2 (en) | 2013-03-14 | 2018-03-06 | Arzeda Corp | recombinant polypeptide with dicamba decarboxylase activity, polynucleotide construct, cell, method of producing a host cell comprising a heterologous polynucleotide encoding a dicamba decarboxylase activity, method for decarboxylating dicamba, a dicamba derivative or a dicamba metabolite, method for detecting a polypeptide and method for detecting the presence of a polynucleotide encoding a polypeptide having dicamba decarboxylase activity |
US20160053277A1 (en) | 2013-03-14 | 2016-02-25 | Pioneer Hi-Bred International, Inc. | Compositions Having Dicamba Decarboxylase Activity and Methods of Use |
MX360160B (en) | 2013-03-15 | 2018-10-24 | Pioneer Hi Bred Int | PHI-4 POLYPEPTIDES and METHODS FOR THEIR USE. |
WO2015023846A2 (en) | 2013-08-16 | 2015-02-19 | Pioneer Hi-Bred International, Inc. | Insecticidal proteins and methods for their use |
EP3043635B1 (en) | 2013-09-13 | 2020-02-12 | Pioneer Hi-Bred International, Inc. | Insecticidal proteins and methods for their use |
MX2016010187A (en) | 2014-02-07 | 2017-07-11 | Pioneer Hi Bred Int | Insecticidal proteins and methods for their use. |
CN114763376A (en) | 2014-02-07 | 2022-07-19 | 先锋国际良种公司 | Insecticidal proteins and methods of use thereof |
US10098943B2 (en) * | 2014-09-11 | 2018-10-16 | Vlp Therapeutics, Llc | Flavivirus virus like particle |
EP3207143B1 (en) | 2014-10-16 | 2023-11-22 | Pioneer Hi-Bred International, Inc. | Insecticidal proteins and methods for their use |
EP3267796B1 (en) | 2015-03-11 | 2023-08-09 | Pioneer Hi-Bred International, Inc. | Insecticidal combinations of pip-72 and methods of use |
CA2985198A1 (en) | 2015-05-19 | 2016-11-24 | Pioneer Hi-Bred International, Inc. | Insecticidal proteins and methods for their use |
CN116003550A (en) | 2015-08-06 | 2023-04-25 | 先锋国际良种公司 | Insecticidal proteins of plant origin and methods of use thereof |
CA3002995A1 (en) | 2015-12-18 | 2017-06-22 | Pioneer Hi-Bred International, Inc. | Insecticidal proteins and methods for their use |
EP3960863A1 (en) | 2016-05-04 | 2022-03-02 | Pioneer Hi-Bred International, Inc. | Insecticidal proteins and methods for their use |
JP6683847B2 (en) * | 2016-06-20 | 2020-04-22 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | Strong and balanced bidirectional promoter |
WO2018005411A1 (en) | 2016-07-01 | 2018-01-04 | Pioneer Hi-Bred International, Inc. | Insecticidal proteins from plants and methods for their use |
CN116003539A (en) | 2016-11-01 | 2023-04-25 | 先锋国际良种公司 | Insecticidal proteins and methods of use thereof |
CN110088123B (en) | 2016-12-14 | 2023-10-20 | 先锋国际良种公司 | Insecticidal proteins and methods of use thereof |
MX2019007491A (en) | 2016-12-22 | 2019-09-06 | Pioneer Hi Bred Int | Insecticidal proteins and methods for their use. |
CA3052794A1 (en) | 2017-02-08 | 2018-08-16 | Pioneer Hi-Bred International, Inc. | Insecticidal combinations of plant derived insecticidal proteins and methods for their use |
RU2019140646A (en) | 2017-05-11 | 2021-06-11 | Пайонир Хай-Бред Интернэшнл, Инк. | INSECTICIDE PROTEINS AND METHODS OF THEIR APPLICATION |
US11820791B2 (en) | 2018-03-14 | 2023-11-21 | Pioneer Hi-Bred International, Inc. | Insecticidal proteins from plants and methods for their use |
BR112020018675A2 (en) | 2018-03-14 | 2021-01-05 | Pioneer Hi-Bred International, Inc. | INSECTICIDE PROTEINS OF PLANTS AND METHODS FOR THEIR USE |
CN113874392A (en) | 2019-03-28 | 2021-12-31 | 丹尼斯科美国公司 | Engineered antibodies |
EP4087932A4 (en) | 2020-01-10 | 2024-01-17 | The Regents of the University of California | Biosynthetic platform for the production of olivetolic avid and analogues of olivetolic acid |
WO2022015619A2 (en) | 2020-07-14 | 2022-01-20 | Pioneer Hi-Bred International, Inc. | Insecticidal proteins and methods for their use |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4882278A (en) * | 1983-04-29 | 1989-11-21 | President And Fellows Of Harvard College | Non-toxinogenic vibrio cholerae mutants |
IL96475A0 (en) * | 1989-11-29 | 1991-08-16 | Innovative Tech Center | Chimeric proteins |
NZ265818A (en) * | 1993-04-19 | 1997-09-22 | Medisorb Technologies Internat | Compositions of nucleic acids encapsulated with molecules that facilitate uptake and integration into living cells |
SG54115A1 (en) * | 1993-04-27 | 1998-11-16 | Gerber Scient Products Inc | Thermal printing apparatus with improved power supply |
WO1994026787A1 (en) * | 1993-05-07 | 1994-11-24 | The Board Of Trustees Of The Leland Stanford Junior University | Method for generating cell type specific phage antibody libraries |
SE9304060D0 (en) * | 1993-12-06 | 1993-12-06 | Bioinvent Int Ab | Methods to select specific bacteriophages |
US6117679A (en) * | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
AU712714B2 (en) * | 1994-10-03 | 1999-11-11 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule B7 gene in a recombinant virus expressing system |
AU4010395A (en) * | 1994-10-27 | 1996-05-23 | Amgen, Inc. | Compositions for increased bioavailability of orally delivered therapeutic agents |
JPH10513350A (en) * | 1995-01-31 | 1998-12-22 | ザ ロックフェラー ユニヴァーシティ | Identification of DEC (dendritic and epithelial cells, 205 kDa), receptor with C-type lectin domain, nucleic acid encoding DEC, and uses thereof |
WO1997007128A1 (en) * | 1995-08-21 | 1997-02-27 | Duke University | A method to increase the density of antigen on antigen presenting cells |
PL325953A1 (en) * | 1995-09-28 | 1998-08-17 | Univ Pittsburgh | Stimulation of immunological responses in which cells are perfprming a mediatory role through addressed genetic immunisation with corpuscules |
US6489145B1 (en) * | 1996-07-09 | 2002-12-03 | Diversa Corporation | Method of DNA shuffling |
WO1997032987A1 (en) * | 1996-03-08 | 1997-09-12 | University Of Toronto | Methods and nucleic immunogenic compositions encoding antigens and co-stimulatory molecules for immunization |
US6096548A (en) * | 1996-03-25 | 2000-08-01 | Maxygen, Inc. | Method for directing evolution of a virus |
-
1999
- 1999-02-10 AU AU32910/99A patent/AU3291099A/en not_active Abandoned
- 1999-02-10 EP EP99932508A patent/EP1056842A2/en not_active Withdrawn
- 1999-02-10 JP JP2000531549A patent/JP2002507392A/en not_active Withdrawn
- 1999-02-10 EP EP99906948A patent/EP1053312A2/en not_active Withdrawn
- 1999-02-10 AU AU26741/99A patent/AU2674199A/en not_active Abandoned
- 1999-02-10 WO PCT/US1999/003022 patent/WO1999041369A2/en not_active Application Discontinuation
- 1999-02-10 JP JP2000531550A patent/JP2002503461A/en not_active Withdrawn
- 1999-02-10 CA CA002320626A patent/CA2320626A1/en not_active Abandoned
- 1999-02-10 CA CA002320431A patent/CA2320431A1/en not_active Abandoned
- 1999-02-10 MX MXPA00007889A patent/MXPA00007889A/en unknown
- 1999-02-10 JP JP2000531583A patent/JP2002503478A/en not_active Withdrawn
- 1999-02-10 WO PCT/US1999/003023 patent/WO1999041402A2/en not_active Application Discontinuation
- 1999-02-10 MX MXPA00007893A patent/MXPA00007893A/en unknown
- 1999-02-10 MX MXPA00007891A patent/MXPA00007891A/en unknown
- 1999-02-10 EP EP99906949A patent/EP1053343A2/en not_active Withdrawn
- 1999-02-10 WO PCT/US1999/003020 patent/WO1999041368A2/en not_active Application Discontinuation
- 1999-02-10 AU AU26742/99A patent/AU2674299A/en not_active Abandoned
- 1999-02-10 CA CA002320960A patent/CA2320960A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1056842A2 (en) | 2000-12-06 |
WO1999041402A2 (en) | 1999-08-19 |
MXPA00007889A (en) | 2002-09-18 |
CA2320960A1 (en) | 1999-08-19 |
WO1999041369A2 (en) | 1999-08-19 |
EP1053343A2 (en) | 2000-11-22 |
WO1999041368A2 (en) | 1999-08-19 |
JP2002507392A (en) | 2002-03-12 |
CA2320626A1 (en) | 1999-08-19 |
WO1999041369A3 (en) | 1999-09-23 |
CA2320431A1 (en) | 1999-08-19 |
AU2674299A (en) | 1999-08-30 |
JP2002503461A (en) | 2002-02-05 |
JP2002503478A (en) | 2002-02-05 |
WO1999041402A3 (en) | 1999-11-11 |
WO1999041368A3 (en) | 1999-12-16 |
MXPA00007891A (en) | 2002-09-18 |
AU2674199A (en) | 1999-08-30 |
EP1053312A2 (en) | 2000-11-22 |
AU3291099A (en) | 1999-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA00007893A (en) | Targeting of genetic vaccine vectors. | |
US20080019988A1 (en) | Targeting of genetic vaccine vectors | |
CA2325351C (en) | Non-stochastic generation of genetic vaccines and enzymes | |
JP4907542B2 (en) | Protein complexes for use in therapy, diagnosis and chromatography | |
US20070087373A1 (en) | Optimization of immunomodulatory properties of genetic vaccines | |
JP4369662B2 (en) | Combinatorial library of monomer domains | |
US20010006950A1 (en) | Genetic vaccine vector engineering | |
US20060286603A1 (en) | Combinatorial libraries of monomer domains | |
JP2012065672A (en) | High affinity tcr protein and method | |
CA2268265A1 (en) | Methods for optimization of gene therapy by recursive sequence shuffling and selection | |
US8754015B2 (en) | Modified phage for displaying post-translationally modified proteins and uses thereof | |
US20020165149A1 (en) | Mutated class II major histocompatibility proteins | |
US20030036506A1 (en) | Mutated class I major histocompatibility proteins and complexes | |
AU2767702A (en) | Targeting of genetic vaccine vectors | |
CA2492661C (en) | Non-stochastic generation of genetic vaccines and enzymes | |
KR20060122623A (en) | Method for measuring effectively the activity of cytotoxic t lymphocyte in human and out-bred animals | |
CN114703229B (en) | Human cell-based surface display technology, HBV receptor targeting polypeptide and application thereof | |
EP1518927A2 (en) | Optimization of immunomodulatory properties of genetic vaccines | |
AU2757902A (en) | Genetic vaccine vector engineering | |
AU2761302A (en) | Optimization of immunomodulatory properties of genetic vaccines |